Method and system for delivering ophthalmic devices

Abstract

The present disclosure provides an ophthalmic article. The ophthalmic article may include a biocompatible matrix including a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also include an active agent or a diagnostic agent. The ophthalmic article may be configured to bond to the haptics of an intraocular lens (IOL).

Description

[Technical Field]

[0001] cross reference

[0001] This application claims priority and benefit to U.S. Provisional Patent Application No. 62 / 867,233 filed on 27 June 2019 and U.S. Provisional Patent Application No. 63 / 012,994 filed on 21 April 2020, each of which is incorporated herein by reference in its entirety. [Background technology]

[0002]

[0002] Cataract surgery is the second most common outpatient surgical procedure in the United States. Patients undergoing cataract surgery may receive a postoperative regimen of topical eye drops that they administer themselves for several weeks after the surgery. These eye drops typically consist of antibiotics to prevent infection, as well as corticosteroids and / or nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent inflammation.

[0003]

[0003] Adherence to postoperative eye drop regimens can be difficult among patients undergoing cataract surgery (e.g., elderly patients). Typical postoperative prophylaxis after cataract surgery may involve complex and lengthy regimens of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and antibiotic eye drops. Patients, particularly the elderly population, may have physical and cognitive impairments that, in addition to visual impairment, limit their ability to read signs, and they must follow instructions and physically administer eye drops to their eyes. Furthermore, many elderly patients live alone and cannot rely on caregivers to administer medication. Therefore, there is a need to develop a system that automatically delivers medication to the eyes to solve the problem of patient non-compliance.

[0004]

[0004] Drug penetration into the eye by topical eye drops can be inefficient. It is estimated that only 1-3% of an eye drop actually penetrates the eye, and once inside the eye, such drugs are removed very rapidly. This can lead to a pulsed delivery profile in which the distributed drug does not cover a continuous range. A more efficient approach may be to release the drug into the inside of the eye, closer to the target tissue, and with a continuous release kinetics.

[0005]

[0005] Cataracts are clouding of the inner lens of the eye that interferes with visual function. Cataracts can occur as a normal part of aging, as well as as a side effect of certain medications, systemic diseases, and genetic conditions. However, cataracts can also be associated with eye trauma, long-term diabetes, corticosteroid medications, or radiation treatments. The standard treatment for cataracts may be a surgical procedure in which the cloudy lens is removed and replaced with an artificial lens (e.g., an intraocular lens) made of clear acrylic or other synthetic material.

[0006]

[0006] An intraocular lens (IOL) device consists of two parts: a central optics and haptics. The optics is the lens portion at the center of the IOL. The haptics are flexible arms that stabilize the IOL inside the lens capsule of the eye. Cataract surgery uses a foldable IOL that can be injected into the eye using a very small incision (2.2-2.8 mm). As a result, suturing to close the eye after cataract surgery is usually not required.

[0007]

[0007] Although drug delivery strategies based on IOLs have been previously investigated, no design has succeeded in creating such a system that requires a change from normal surgical techniques or the addition of an extra step to the manufacturing process without significant modifications to the IOL design. For example, one of the preceding IOLs consists of two dexamethasone-PLGA pellets embedded in an optics, but the implantation required a 6 mm incision and two sutures, which was three times the current standard size for a sutureless corneal incision. Thus, this approach is not practical in modern cataract surgery.

[0008]

[0008] While previous ring-shaped drug delivery devices attached to the haptics of a three-piece IOL, their size and rigidity were incompatible with standard cataract surgery techniques because the devices required delivery through a larger corneal incision than those currently in use. Therefore, this approach was also not ideal.

[0009]

[0009] Other prior approaches require immersing the IOL in a drug solution before surgery, but this approach is limited by the compatibility of the specific drug with the specific IOL matrix material (e.g., water-soluble antibiotics for acrylic lenses; corticosteroids for silicone lenses). Furthermore, this approach does not exhibit controlled release; on the contrary, it is merely a burst release with limited diffusion.

[0010]

[0010] In another example, a system has been previously proposed in which an ultrathin clear film that releases a drug is fabricated on the surface of the IOL without impairing the optical properties of the lens. While it seems reasonable that this device would achieve sufficient drug release function and would not require any changes to the usual cataract surgery procedure, this system adds an additional step to the manufacturing process, thereby affecting the overall cost of the product. Furthermore, it is not readily applicable to IOLs of various sizes, shapes, and refractive powers or materials, and doing so may require the manufacturer to add this feature separately to the IOL's construction and model for each individual. [Overview of the project] [Problems that the invention aims to solve]

[0011]

[0011] Improved ophthalmic articles, devices, methods, systems and kits are desirable for delivering or administering activators and / or diagnostic agents from an ophthalmic device to the eye, and / or addressing at least some of the above drawbacks. [Means for solving the problem]

[0012]

[0012] Embodiments of the present disclosure provide articles, methods, devices, systems, and kits for the delivery of intraocular agents (e.g., activators and / or diagnostic agents). The present disclosure provides articles, methods, systems, and kits for the delivery or administration of activators and / or diagnostic agents to the eye from an ophthalmic device. The present disclosure also provides articles, methods, systems, and kits for the diagnosis and / or treatment of ophthalmic diseases, conditions, and / or complications.

[0013]

[0013] In one embodiment, the present disclosure provides an ophthalmic article. In one embodiment, the ophthalmic article comprises (a) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, and (b) an activator or diagnostic agent, configured to bind to the haptics of an intraocular lens (IOL). In some embodiments, the copolymer is derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the copolymer is derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the biocompatible matrix is ​​a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer comprises a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, the ophthalmic article has a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, the ophthalmic article has a tensile strength of about 25 MPa to 35 MPa. In some embodiments, the ophthalmic article has a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, the ophthalmic article has a glass transition temperature of about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, the ophthalmic article has an elastic modulus of at most about 3 MPa. In some embodiments, the ophthalmic article has an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, the ophthalmic article has an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, the ophthalmic article has an elongation at break of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of the ophthalmic article is a ring, an extruded ring, a torus, or a prism with a hole in the center.In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism of another shape. In some embodiments, the ophthalmic article includes an internal structure for coupling around the haptics of the IOL. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the haptics of the IOL. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of the haptics of the IOL. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of the haptics of the IOL. In some embodiments, when the ophthalmic article is coupled to the haptics of the IOL, it extends beyond the haptics of the IOL to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of the haptics of the IOL. In some embodiments, the ophthalmic article includes an internal structure for fixing around the notched area of ​​the haptics of the IOL. In some embodiments, the ophthalmic article has an outer diameter of at most 1.5 mm. In some embodiments, the ophthalmic article includes an internal bore having a diameter of at most 0.7 mm. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral drug, an antimetabolite, an antifungal drug, an antifibrotic agent, or an angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured so that the activator or diagnostic agent is released from the biocompatible matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for about 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm.In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the eye of the subject. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0014]

[0014] In another embodiment, the present disclosure provides ophthalmic articles. In one embodiment, an ophthalmic article comprises (a) a biocompatible material and (b) an activator or diagnostic agent, and has equivalent elasticity, compressibility, tensile strength, shape recovery, or reformability to another article comprising a biocompatible matrix comprising a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of lactide monomer, and is configured to bond to the haptics of an intraocular lens (IOL). In some embodiments, the biocompatible material comprises a copolymer matrix. In some embodiments, the biocompatible material comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to about 80% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the other article comprising the biocompatible material or biocompatible matrix comprises a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, another article containing a biocompatible material or biocompatible matrix comprises a random copolymer. In some embodiments, another article containing a biocompatible material or biocompatible matrix is ​​biodegradable. In some embodiments, another article contains another activator or diagnostic agent. In some embodiments, another article containing a biocompatible matrix has a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, another article containing a biocompatible matrix has a tensile strength of about 25 MPa to 35 MPa. In some embodiments, another article containing a biocompatible matrix has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, another article containing a biocompatible matrix has a glass transition temperature of about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, another article containing a biocompatible matrix has an elastic modulus of at most about 3 MPa. In some embodiments, another article containing a biocompatible matrix has an elastic modulus of about 0.5 MPa to 3 MPa.In some embodiments, another article containing a biocompatible matrix has a break elongation of at least about 100% when measured at about 18°C ​​to 24°C. In some embodiments, another article containing a biocompatible matrix has a break elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of the ophthalmic article is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the ophthalmic article includes an internal structure for coupling around the haptics of the IOL. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the haptics of the IOL. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of the haptics of the IOL. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of the haptics of the IOL. In some embodiments, the ophthalmic article extends beyond the IOL haptics to about 0.32 mm or less once it is attached to the IOL haptics. In some embodiments, the shape of the internal structure is the same as the shape of the IOL haptics. In some embodiments, the ophthalmic article includes an internal structure for fixation around the notched area of ​​the IOL haptics. In some embodiments, the ophthalmic article includes an outer diameter of at most 1.5 mm. In some embodiments, the ophthalmic article includes an inner bore with a diameter of at most 0.7 mm. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, corticosteroid, nonsteroidal anti-inflammatory drug, antibiotic, antiviral drug, antimetabolite, antifungal drug, antifibrotic agent, or angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured so that an activator or diagnostic agent is released from a biocompatible material. In some embodiments, the activator or diagnostic agent is released from the biocompatible material for at least about 7 days.In some embodiments, the activator or diagnostic agent is released from the biocompatible material over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible material by the decomposition of the biocompatible material. In some embodiments, the ophthalmic article or another article containing a biocompatible matrix is ​​sufficiently compressible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the ophthalmic article or another article containing a biocompatible matrix is ​​sufficiently flexible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the ophthalmic article or another article containing a biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not undergo significant changes in shape within at least 7 days after implantation in the eye of the subject. In some embodiments, the ophthalmic article contains one or more active and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0015]

[0015] In one embodiment, the present disclosure provides an ophthalmic system. In one embodiment, the ophthalmic delivery system comprises (a) one or more ophthalmic articles comprising (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, and (2) one or more activators or diagnostic agents, and (b) one or more intraocular lenses (IOLs) comprising one or more haptics, wherein one or more ophthalmic articles are bonded to one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is bonded to one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are bonded to one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are bonded to one or more haptics of the IOL. In some embodiments, about one of one or more ophthalmic articles is bonded to one of one or more haptics of an IOL. In some embodiments, two of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, the copolymer is derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the copolymer is derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa).In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more ophthalmic articles have an elongation at break of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism having three or more sides, or a prism having another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral drug, an antimetabolite, an antifungal drug, an antifibrotic agent, or an angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics of an IOL. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the haptics of the IOL. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics of the IOL. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics of the IOL. In some embodiments, when one or more ophthalmic articles are coupled to one or more haptics of an IOL, they extend beyond one or more haptics of the IOL to about 0.32 mm or less.In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics of the IOL. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics of the IOL. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, one or more ophthalmic articles include an inner diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured so that an activator or diagnostic agent is released from the biocompatible matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for about 5 to 30 days, 5 to 21 days, 5 to 14 days, 5 to 10 days, 7 to 30 days, 7 to 21 days, 7 to 14 days, or 7 to 10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the eye of the subject. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0016]

[0016] In another embodiment, the present disclosure provides a method for treating or preventing a disease. In one embodiment, the method comprises the step of implanting an intraocular lens (IOL) for sustained intraocular drug delivery into the eye of a subject requiring treatment or prevention of a disease, the IOL comprising one or more drug-releasing articles bound thereto, the one or more drug-releasing articles comprising one or more activators, and within 7 days after implantation, the one or more drug-releasing articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy, or ocular pain being eliminated as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation, the one or more drug-releasing articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy. In some embodiments, within 7 days after implantation, the one or more drug-releasing articles release one or more activators, resulting in ocular pain being eliminated as measured by a 10-point visual analog scale. In some embodiments, one or more drug-releasing articles are coupled to one or more haptics of the IOL. In some embodiments, about one of the one or more drug-releasing articles is coupled to one or more haptics of the IOL. In some embodiments, about two of the one or more drug-releasing articles are coupled to one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more drug-releasing articles are coupled to one or more haptics of the IOL. In some embodiments, about one of the one or more drug-releasing articles is coupled to one of the one or more haptics of the IOL. In some embodiments, about two of the one or more drug-releasing articles are coupled to one of the one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more drug-releasing articles are coupled to one of the one or more haptics of the IOL. In some embodiments, one or more drug-releasing articles include a biocompatible matrix.In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more drug-releasing articles are configured to release an activator from the biocompatible matrix. In some embodiments, the activator is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator is released from the biocompatible matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator is released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, one or more drug-releasing articles have a tensile strength of at least approximately 0.5 megapascals (MPa). In some embodiments, one or more drug-releasing articles have a tensile strength of approximately 25 MPa to 35 MPa.In some embodiments, one or more drug-releasing articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more drug-releasing articles have a glass transition temperature of at most about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more drug-releasing articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more drug-releasing articles have an elastic modulus of at least about 0.5 MPa to 3 MPa. In some embodiments, one or more drug-releasing articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more drug-releasing articles have an elongation at break of at least 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more drug-releasing articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, corticosteroid, nonsteroidal anti-inflammatory drug, antibiotic, antiviral drug, antimetabolite, antifungal drug, antifibrotic agent, or angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, one or more drug-releasing articles include an internal structure for binding around one or more haptics of an IOL. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the haptics of the IOL. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, one or more drug-releasing articles extend beyond one or more haptics to about 0.32 mm or less once the one or more drug-releasing articles are bound to one or more haptics. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics.In some embodiments, one or more drug-releasing articles include an internal structure for securing around the notched area of ​​one or more haptics. In some embodiments, one or more drug-releasing articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more drug-releasing articles are compressed and bonded to the outward-facing surface of one or more haptics. In some embodiments, one or more drug-releasing articles are bonded to one or more haptics of the IOL. In some embodiments, the method includes the step of compressing the IOL to which one or more drug-releasing articles are bonded through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm before implantation in the eye of the subject. In some embodiments, the compression includes the step of folding the IOL to which one or more drug-releasing articles are bonded into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the subject is currently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is currently undergoing or has undergone cataract surgery. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not undergo significant changes in shape within at least 7 days after implantation in the eye of the subject. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0017]

[0017] In another embodiment, the present disclosure provides a method for treating or preventing a disease. In one embodiment, the method comprises (a) attaching one or more ophthalmic articles to one or more haptics of at least one intraocular lens (IOL) to thereby generate at least one activator-releasing intraocular lens, and (b) implanting at least one activator-releasing intraocular lens in the eye of a subject requiring treatment or prevention of a disease for sustained intraocular activator delivery, wherein within 7 days after implantation, one or more ophthalmic articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy, or ocular pain being eliminated as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation, one or more ophthalmic articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy. In some embodiments, within 7 days of implantation, one or more ophthalmic articles release one or more activators, resulting in the elimination of eye pain as measured by a 10-point visual analog scale. In some embodiments, about one of the one or more ophthalmic articles is coupled with one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are coupled with one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are coupled with one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is coupled with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are coupled with one of the one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are coupled with one of the one or more haptics. In some embodiments, one or more ophthalmic articles include a biocompatible matrix.In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles are configured so that an activator is released from the biocompatible matrix. In some embodiments, the activator is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator is released from the biocompatible matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator is released from the biocompatible matrix by decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, one or more ophthalmic articles have a tensile strength of at least approximately 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of approximately 25 MPa to 35 MPa.In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of at least about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more ophthalmic articles have an elongation at break of at least 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, corticosteroid, nonsteroidal anti-inflammatory drug, antibiotic, antiviral drug, antimetabolite, antifungal drug, antifibrotic agent, or angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the binding includes an indirect binding between one or more ophthalmic articles and one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, when one or more ophthalmic articles are bonded to one or more haptics, they extend beyond one or more haptics to about 0.32 mm or less.In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for securing around the notch region of one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are compression-bonded to the outer-facing surface of one or more haptics. In some embodiments, the method includes compressing at least one active agent-releasing intraocular lens through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm prior to implantation into the subject's eye. In some embodiments, the compression includes folding at least one active agent-releasing intraocular lens tubularly through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the subject is undergoing or has undergone an ophthalmic surgery. In some embodiments, the subject is undergoing or has undergone a cataract surgery. In some embodiments, the bonding includes a direct bond between one or more ophthalmic articles and one or more haptics by chemical bonding, physical bonding, compressive force, or contractive force. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article resumes its shape when implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiological environment so as not to significantly change shape within at least 7 days after implantation of the ophthalmic article in the subject's eye. In some embodiments, the ophthalmic article includes one or more active agents and / or diagnostic agents of about 1 μg to 800 μg.

[0018]

[0018] In another embodiment, the present disclosure provides a method for treating or preventing a disease. In one embodiment, the method includes (a) combining one or more activators with a biocompatible matrix to produce one or more ophthalmic articles; (b) attaching one or more ophthalmic articles to one or more haptics of at least one intraocular lens to produce at least one activator-releasing intraocular lens; and (c) implanting at least one activator-releasing intraocular lens in the eye of a subject requiring treatment or prevention of a disease for sustained intraocular activator delivery, wherein within 7 days after implantation, one or more ophthalmic articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy, or ophthalmic pain being eliminated as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation, one or more ophthalmic articles release one or more activators, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy. In some embodiments, within 7 days of implantation, one or more ophthalmic articles release one or more activators, resulting in the elimination of eye pain as measured by a 10-point visual analog scale. In some embodiments, about one of the one or more ophthalmic articles is coupled with one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are coupled with one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are coupled with one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is coupled with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are coupled with one of the one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are coupled with one of the one or more haptics.In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more ophthalmic articles have an elongation at break of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, one or more activators are intraocular pressure (IOP) lowering agents, corticosteroids, nonsteroidal anti-inflammatory drugs, antibiotics, antivirals, antimetabolites, antifungals, antifibrotics, or angiogenesis inhibitors.In some embodiments, one or more activators are dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the binding includes an indirect binding between one or more ophthalmic articles and one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, when one or more ophthalmic articles are bound to one or more haptics, one or more ophthalmic articles extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for securing around one or more haptic notch areas. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured so that an activator is released from a biocompatible copolymer matrix. In some embodiments, the activator is released from the biocompatible matrix over a period of at least about 7 days. In some embodiments, the activator is released from the biocompatible matrix over a period of about 5 to 30 days, 5 to 21 days, 5 to 14 days, 5 to 10 days, 7 to 30 days, 7 to 21 days, 7 to 14 days, or 7 to 10 days. In some embodiments, the activator is released from the biocompatible matrix by decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm.In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm, and one or more ophthalmic articles are compressed and bonded to the outward surface of one or more haptics. In some embodiments, the method includes the step of compressing at least one activator-releasing intraocular lens through an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm before implanting at least one activator-releasing intraocular lens in the subject's eye. In some embodiments, the compression includes the step of folding at least one activator-releasing intraocular lens into a tubular shape through an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the subject is currently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is currently undergoing or has undergone cataract surgery. In some embodiments, the bonding includes direct bonding between one or more ophthalmic articles and one or more haptics by chemical bonding, physical bonding, compressive force, or contractile force. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the subject's eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of about 1 μg to 800 μg.

[0019]

[0019] In another embodiment, the present disclosure provides a method for preparing at least one ophthalmic article. In one embodiment, the method includes (a) combining one or more activators or diagnostic agents in a solvent with a biocompatible matrix in a solvent to produce a combined mixture in the solvent; (b) removing the solvent from the combined mixture to produce an evaporated mixture; (c) compressing the evaporated mixture using a weighting tool to produce a compressed mixture; and (d) extracting at least one ophthalmic article from the compressed mixture using a molding tool and an orifice tool. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, at least one ophthalmic article has a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, at least one ophthalmic article has a tensile strength of about 25 MPa to 35 MPa. In some embodiments, at least one ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, at least one ophthalmic article has a glass transition temperature of about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, at least one ophthalmic article has an elastic modulus of at most about 3 MPa. In some embodiments, at least one ophthalmic article has an elastic modulus of about 0.5 MPa to 3 MPa.In some embodiments, at least one ophthalmic article has a break elongation of at least about 100% as measured by a tensile test. In some embodiments, at least one ophthalmic article has a break elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of at least one ophthalmic article is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, one or more active agents are intraocular pressure (IOP) lowering agents, corticosteroids, nonsteroidal anti-inflammatory drugs, antibiotics, antivirals, antimetabolites, antifungals, antifibrotics, or angiogenic inhibitors. In some embodiments, one or more activators are dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, at least one ophthalmic article includes an internal structure for binding around one or more haptics of the intraocular lens. In some embodiments, at least one ophthalmic article includes an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, at least one ophthalmic article is configured so that one or more activators or diagnostic agents are released from the biocompatible matrix. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix by decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm.In some embodiments, the method includes suspending one or more active agents or diagnostic agents in a solvent prior to the combination in (a), thereby generating a suspension. In some embodiments, the weighting tool is a steel plate. In some embodiments, the weighting tool is a heated steel plate. In some embodiments, the weighting tool is a heated steel plate coated with Teflon (registered trademark). In some embodiments, the weighting tool compresses the evaporated mixture onto a sheet. In some embodiments, the biocompatible matrix is sufficiently elastic such that when implanted intraocularly, the ophthalmic article will regain its shape. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiological environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the eye of a subject. In some embodiments, the ophthalmic article comprises one or more active agents and / or diagnostic agents from about 1 μg to 800 μg.

[0020]

[0020] In another embodiment, the present disclosure provides a method for preparing at least one activator-releasing intraocular lens. In one embodiment, the method includes (a) combining one or more activators or diagnostic agents with a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer to produce one or more ophthalmic articles; and (b) binding one or more ophthalmic articles to one or more haptics of at least one intraocular lens (IOL). In some embodiments, about one of the one or more ophthalmic articles is bound to one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is bound to one of the one or more haptics of the IOL. In some embodiments, about two of one or more ophthalmic articles are bonded to one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one or more haptics of an IOL. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable.In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more ophthalmic articles have an elongation at break of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral drug, an antimetabolite, an antifungal drug, an antifibrotic agent, or an angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the binding includes an indirect binding between one or more ophthalmic articles and one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics.In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, one or more ophthalmic articles, when coupled to one or more haptics, extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured to release one or more activators or diagnostic agents from the biocompatible matrix. In some embodiments, the activators or diagnostic agents are released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix by the degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, one or more ophthalmic articles are compressed and bonded to the outward-facing surface of one or more haptics.In some embodiments, the method includes compressing an IOL to which one or more ophthalmic articles are bound through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm prior to implantation in the target eye. In some embodiments, the compression includes folding the IOL to which one or more ophthalmic articles are bound into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the binding includes direct binding between one or more ophthalmic articles and one or more haptics by chemical binding, physical binding, compressive force, or contractile force. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic articles regain their shape once implanted in the eye. In some embodiments, the ophthalmic articles are sufficiently physically stable in the physiological environment so that they do not significantly change shape within at least 7 days after implantation of the ophthalmic articles in the target eye. In some embodiments, the ophthalmic articles contain one or more activators and / or diagnostic agents in an amount of about 1 μg to 800 μg.

[0021]

[0021] In another embodiment, the present disclosure provides a method for administering an activator or diagnostic agent. In one embodiment, the method includes (a) coupling one or more ophthalmic articles to one or more haptics of at least one intraocular lens to generate at least one activator-releasing intraocular lens; (b) compressing at least one activator-releasing intraocular lens through an intraocular lens injector having an injector tip inner diameter of about 0.5 mm to 3 mm; and (c) implanting at least one activator-releasing intraocular lens into the eye of a subject requiring administration of an activator or diagnostic agent for sustained intraocular activator or diagnostic agent delivery. In some embodiments, about one of the one or more ophthalmic articles is coupled to one or more haptics of an IOL. In some embodiments, about two of the one or more ophthalmic articles are coupled to one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one or more haptics of an IOL. In some embodiments, about one of one or more ophthalmic articles is bonded to one of one or more haptics of an IOL. In some embodiments, about two of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, one or more ophthalmic articles include a biocompatible matrix. In some embodiments, the biocompatible matrix includes a copolymer derived from about 20% to about 60% by weight of a caprolactone monomer and about 40% to about 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of a caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer.In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles are configured so that an activator or diagnostic agent is released from the biocompatible matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for about 5 to 30 days, 5 to 21 days, 5 to 14 days, 5 to 10 days, 7 to 30 days, 7 to 21 days, 7 to 14 days, or 7 to 10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix by decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, one or more ophthalmic articles have a tensile strength of at least approximately 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of approximately 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most approximately 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of approximately -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most approximately 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of approximately 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least approximately 100% as measured by a tensile test.In some embodiments, one or more ophthalmic articles have a break elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral drug, an antimetabolite, an antifungal drug, an antifibrotic agent, or an angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the binding includes an indirect binding between one or more ophthalmic articles and one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for coupling around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, when one or more ophthalmic articles are coupled to one or more haptics, they extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, one or more ophthalmic articles include an inner diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are compressed and bonded to the outward-facing surface of one or more haptics.In some embodiments, compression includes the step of folding at least one activator-releasing intraocular lens into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the subject is undergoing or has undergone ophthalmic surgery simultaneously. In some embodiments, the subject is undergoing or has undergone cataract surgery simultaneously. In some embodiments, bonding includes direct bonding between one or more ophthalmic articles and one or more haptics by chemical bonding, physical bonding, compressive force, or contractile force. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the subject's eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of about 1 μg to 800 μg.

[0022]

[0022] In another embodiment, the present disclosure provides a method for administering an activator or diagnostic agent. In one embodiment, the method includes (a) compressing an intraocular lens (IOL) to which one or more ophthalmic articles are bound through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm, thereby producing a compressed IOL to which one or more ophthalmic articles are bound, wherein one or more ophthalmic articles contain one or more activators or diagnostic agents; and (b) implanting the compressed IOL to which one or more ophthalmic articles are bound into the eye of a subject requiring administration of the activator or diagnostic agent for sustained intraocular activator or diagnostic agent delivery. In some embodiments, about one of the one or more ophthalmic articles is bound to one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one or more haptics of an IOL. In some embodiments, about one of one or more ophthalmic articles is bonded to one of one or more haptics of an IOL. In some embodiments, about two of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, one or more ophthalmic articles include a biocompatible matrix. In some embodiments, the biocompatible matrix includes a copolymer derived from about 20% to about 60% by weight of a caprolactone monomer and about 40% to about 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate.In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles are configured to release one or more activators or diagnostic agents from the biocompatible matrix. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix for at least about 7 days. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix for about 5 to 30 days, 5 to 21 days, 5 to 14 days, 5 to 10 days, 7 to 30 days, 7 to 21 days, 7 to 14 days, or 7 to 10 days. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, one or more ophthalmic articles have a tensile strength of at least approximately 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of approximately 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most approximately 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of approximately -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most approximately 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of approximately 0.5 MPa to 3 MPa.In some embodiments, one or more ophthalmic articles have a break elongation of at least about 100% as measured by a tensile test. In some embodiments, one or more ophthalmic articles have a break elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or prism with a hole in the center. In some embodiments, the prism is a circular prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, corticosteroid, nonsteroidal anti-inflammatory drug, antibiotic, antiviral drug, antimetabolite, antifungal drug, antifibrotic agent, or angiogenic inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, one or more ophthalmic articles are indirectly coupled to one or more haptics of the IOL. In some embodiments, one or more ophthalmic articles include an internal structure for coupling around one or more haptics of the intraocular lens. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics of the IOL. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics of the IOL. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics of the IOL. In some embodiments, when one or more ophthalmic articles are coupled to one or more haptics of the IOL, they extend beyond one or more haptics of the IOL to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics of the IOL. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics of the IOL. In some embodiments, one or more ophthalmic articles have an outer diameter of at most 1.5 mm. In some embodiments, the internal structure has a diameter of at most 0.7 mm.In some embodiments, one or more ophthalmic articles are bonded to one or more haptics of an IOL. In some embodiments, one or more ophthalmic articles are compressed and bonded to the outward surface of one or more haptics of an IOL. In some embodiments, one or more ophthalmic articles are directly bonded to one or more ophthalmic articles and one or more haptics by chemical bonding, physical bonding, compressive force, or contractile force. In some embodiments, compression includes the step of folding the IOL to which one or more ophthalmic articles are bonded into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the subject is undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is undergoing or has undergone cataract surgery. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the subject's eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0023]

[0023] In another embodiment, the Disclosure provides a kit. In one embodiment, the kit includes a container, which includes instructions for use, and one or more ophthalmic articles, which include (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, and (2) one or more activators or diagnostic agents. In some embodiments, the kit further includes another container comprising one or more intraocular lenses, each of the one or more intraocular lenses comprising one or more haptics. In some embodiments, the container further includes one or more intraocular lenses, each comprising one or more haptics conjugated to one or more ophthalmic articles. In some embodiments, one or more ophthalmic articles are conjugated to one or more haptics of one or more IOLs. In some embodiments, about one of the one or more ophthalmic articles is conjugated to one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are conjugated to one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one or more haptics. In some embodiments, about one of one or more ophthalmic articles is bonded to one of one or more haptics. In some embodiments, about two of one or more ophthalmic articles are bonded to one of one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, at least one other monomer is lactide, glycolide, or trimethylene carbonate.In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100% as measured by a tensile test. In some embodiments, one or more ophthalmic articles have a break point elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or a prism with a hole in the center. In some embodiments, the prism is a cylindrical prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, one or more activators are intraocular pressure (IOP) lowering agents, corticosteroids, nonsteroidal anti-inflammatory drugs, antibiotics, antivirals, antimetabolites, antifungals, antifibrotic agents, or angiogenesis inhibitors. In some embodiments, one or more activators are dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics.In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, one or more ophthalmic articles, when coupled to one or more haptics, extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured to release an activator or diagnostic agent from the biocompatible matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm–3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye.In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so as not to undergo significant changes in shape within at least 7 days after implantation of the ophthalmic article within the target eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0024]

[0024] In another embodiment, the present disclosure provides a method for diagnosing a disease or condition of the eye. In one embodiment, the method includes the step of administering an intraocular lens (IOL) to an eye of a subject that requires it, the IOL comprising one or more ophthalmic articles bound thereto, the one or more ophthalmic articles comprising one or more diagnostic agents selected from the group consisting of paramagnetic molecules, fluorescent compounds, magnetic molecules, radionuclides, X-ray imaging agents and contrast agents. In some embodiments, the method further includes the step of capturing an image in which the one or more diagnostic agents indicate a disease or condition. In some embodiments, the method includes the step of binding one or more ophthalmic articles to one or more haptics of the IOL prior to administering the IOL to which the one or more ophthalmic articles are bound. In some embodiments, the method includes the step of combining one or more diagnostic agents with a biocompatible copolymer matrix prior to administering the IOL to which the one or more ophthalmic articles are bound, thereby generating one or more ophthalmic articles. In some embodiments, the method includes the step of compressing the IOL to which one or more ophthalmic articles are bound through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm, prior to administering the IOL to which one or more ophthalmic articles are bound. In some embodiments, one or more diagnostic agents are fluorescent compounds. In some embodiments, one or more ophthalmic articles include a biocompatible matrix. In some embodiments, one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is bound to one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of the one or more ophthalmic articles are bound to one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is bound to one of the one or more haptics of the IOL.In some embodiments, about two of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics of an IOL. In some embodiments, one or more ophthalmic articles include a biocompatible matrix. In some embodiments, the biocompatible matrix includes a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix includes a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles are configured so that a diagnostic agent is released from the biocompatible matrix. In some embodiments, the diagnostic agent is released from the biocompatible matrix by the decomposition of the biocompatible matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection with an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection with an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection with an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa.In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about -20°C to 24°C, as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of at least about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100%, as measured by tensile testing. In some embodiments, one or more ophthalmic articles have an elongation at break of at least 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or a prism with a hole in the center. In some embodiments, the prism is a cylindrical prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, one or more ophthalmic articles include an internal structure for bonding around one or more haptics of an IOL. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, when one or more ophthalmic articles are bonded to one or more haptics, they extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, the internal structure includes a diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are compressed and bonded to the outward-facing surface of one or more haptics.In some embodiments, one or more ophthalmic articles are bonded to one or more haptics of the IOL. In some embodiments, compression includes the step of folding the IOL to which one or more ophthalmic articles are bonded into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the eye of the subject. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of about 1 μg to 800 μg.

[0025]

[0025] In another embodiment, the present disclosure provides a method for administering an activator or diagnostic agent. In one embodiment, the method includes (a) combining one or more activators or diagnostic agents with a biocompatible matrix to produce one or more ophthalmic articles; (b) binding one or more ophthalmic articles to one or more haptics of at least one intraocular lens to produce at least one activator-releasing intraocular lens; (c) compressing at least one activator-releasing intraocular lens through an intraocular lens injector having an injector tip inner diameter of about 0.5 mm to 3 mm; and (d) implanting at least one activator-releasing intraocular lens in the eye of a subject requiring it in order to continuously deliver the intraocular activator or diagnostic agent. In some embodiments, about one of the one or more ophthalmic articles is bound to one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are bound to one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one or more haptics. In some embodiments, about one of one or more ophthalmic articles is bonded to one of one or more haptics. In some embodiments, about two of one or more ophthalmic articles are bonded to one of one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are bonded to one of one or more haptics. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer.In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is ​​biodegradable. In some embodiments, one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa). In some embodiments, one or more ophthalmic articles have a tensile strength of about 25 MPa to 35 MPa. In some embodiments, one or more ophthalmic articles have a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have a glass transition temperature of about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, one or more ophthalmic articles have an elastic modulus of at most about 3 MPa. In some embodiments, one or more ophthalmic articles have an elastic modulus of about 0.5 MPa to 3 MPa. In some embodiments, one or more ophthalmic articles have an elongation at break of at least about 100% as measured by a tensile test. In some embodiments, one or more ophthalmic articles have a break point elongation of about 500% to 1500% at about 18°C ​​to 24°C. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or a prism with a hole in the center. In some embodiments, the prism is a cylindrical prism, a rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral agent, an antimetabolite, an antifungal agent, an antifibrotic agent, or an angiogenesis inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the binding includes an indirect binding between one or more ophthalmic articles and one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for bonding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics.In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, one or more ophthalmic articles extend beyond one or more haptics to about 0.32 mm or less when the one or more ophthalmic articles are bonded to one or more haptics. In some embodiments, the shape of the internal structure is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixation around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an outer diameter of at most 1.5 mm. In some embodiments, one or more ophthalmic articles include an inner diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured so that an activator or diagnostic agent is released from the biocompatible copolymer matrix. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix for at least about 7 days. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, one or more activators or diagnostic agents are released from the biocompatible matrix by degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip diameter of approximately 0.5 mm to 3 mm. In some embodiments, one or more ophthalmic articles are compressed and bonded to the outward-facing surface of one or more haptics.In some embodiments, compression involves folding at least one activator-releasing intraocular lens into a tubular shape through an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm. In some embodiments, the subject is undergoing or has undergone ophthalmic surgery simultaneously. In some embodiments, the subject is undergoing or has undergone cataract surgery simultaneously. In some embodiments, bonding involves direct bonding between one or more ophthalmic articles and one or more haptics by chemical bonding, physical adhesion, compressive force, or contractile force. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the subject's eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of about 1 μg to 800 μg.

[0026]

[0026] In another embodiment, the present disclosure provides an ophthalmic drug delivery system. In one embodiment, the ophthalmic drug delivery system comprises (a) (1) one or more active or diagnostic agents, and (2) a biocompatible copolymer matrix derived from about 40% by weight of caprolactone monomer and 60% by weight of lactide monomer, characterized by: (i) the biocompatible copolymer matrix contains random copolymers, (ii) one or more ophthalmic articles having a tensile strength of about 25 megapascals (MPa) to 35 MPa, (iii) one or more ophthalmic articles having a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry, and (iv) one or more ophthalmic articles having about 0.5 (v) one or more ophthalmic articles comprising a biocompatible copolymer matrix having an elastic modulus of MPa to 3 MPa, with at least one of which has a breaking elongation of about 500% to 1500% at about 18°C ​​to 24°C; and (b) one or more intraocular lenses (IOLs) comprising one or more haptics, each having an outer diameter of at most 1.5 mm, and configured to bond to the outward surface of one or more haptics of one or more IOLs for fixation of one or more ophthalmic articles to one or more haptics of one or more IOLs. In some embodiments, about one of the one or more ophthalmic articles is bonded to one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are bonded to one or more haptics. In some embodiments, about three, four, five, six, seven, eight, nine or ten of the one or more ophthalmic articles are bonded to one or more haptics. In some embodiments, about one of one or more ophthalmic articles is coupled to one of one or more haptics of the IOL. In some embodiments, about two of one or more ophthalmic articles are coupled to one of one or more haptics of the IOL. In some embodiments, about three, four, five, six, seven, eight, nine, or ten of one or more ophthalmic articles are coupled to one of one or more haptics of the IOL.In some embodiments, the biocompatible copolymer matrix is ​​biodegradable. In some embodiments, the shape of one or more ophthalmic articles is an annular, extruded annular, torus, or a prism with a central hole. In some embodiments, the prism is a cylindrical prism, a rectangular prism, a prism with three or more sides, or a prism of another shape. In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, a corticosteroid, a nonsteroidal anti-inflammatory drug, an antibiotic, an antiviral agent, an antimetabolite, an antifungal agent, an antifibrotic agent, or an angiogenesis inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, one or more ophthalmic articles include an internal structure for binding around one or more haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of one or more haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of one or more haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of one or more haptics. In some embodiments, when one or more ophthalmic articles are coupled to one or more haptics, they extend beyond one or more haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure of one or more ophthalmic articles is the same as the shape of one or more haptics. In some embodiments, one or more ophthalmic articles include an internal structure for fixing around the notched area of ​​one or more haptics. In some embodiments, one or more ophthalmic articles include an inner diameter of at most 0.7 mm. In some embodiments, one or more ophthalmic articles are configured so that an activator or diagnostic agent is released from the biocompatible copolymer matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix for at least about 7 days.In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix over a period of approximately 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix by the degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently compressible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently flexible to accommodate injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently elastic to recover its original shape after injection by an IOL injector with an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not undergo significant changes in shape within at least 7 days after implantation in the eye of the subject. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0027]

[0027] In another embodiment, the present disclosure provides an ophthalmic article. In one embodiment, the ophthalmic article comprises (a) a biocompatible copolymer matrix derived from about 40% by weight of caprolactone monomer and 60% by weight of lactide monomer, characterized by at least one of the following: (i) the biocompatible copolymer matrix contains random copolymers, (ii) the ophthalmic article has a tensile strength of about 25 megapascals (MPa) to 35 MPa, (iii) the ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry, (iv) the ophthalmic article has an elastic modulus of about 0.5 MPa to 3 MPa, and (v) the ophthalmic article has an elongation at break of about 500% to 1500% at 18°C ​​to 24°C, and (b) an activator or diagnostic agent, the ophthalmic article having an outer diameter of at most 1.5 mm, and is configured to bond to the outward surface of the haptics of an intraocular lens (IOL) for fixation of the ophthalmic article to the haptics of the IOL. In some embodiments, the biocompatible copolymer matrix is ​​biodegradable. In some embodiments, the shape of the ophthalmic article is an annular, extruded annular, torus, or a prism with a hole in the center, and may be circular, rectangular, or other shapes. In some embodiments, the prism is a cylindrical prism, a cuboid prism, a prism with three or more sides, or a prism of another shape. In some embodiments, the ophthalmic article includes an internal structure for bonding around the outward-facing surface of the IOL haptics. In some embodiments, the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the IOL haptics. In some embodiments, the perimeter of the internal structure is less than or equal to the perimeter of the IOL haptics. In some embodiments, the maximum width of the internal structure is less than or equal to the maximum width of the IOL haptics. In some embodiments, when the ophthalmic article is bonded to the IOL haptics, it stretches beyond the IOL haptics to about 0.32 mm or less. In some embodiments, the shape of the internal structure is the same as the shape of the IOL haptics. In some embodiments, the ophthalmic article includes an internal structure for securing it around the haptic notch area of ​​the IOL. In some embodiments, the ophthalmic article includes an internal bore having a diameter of at most 0.7 mm.In some embodiments, the activator is an intraocular pressure (IOP) lowering agent, corticosteroid, nonsteroidal anti-inflammatory drug, antibiotic, antiviral agent, antimetabolite, antifungal agent, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the activator is dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured so that the activator or diagnostic agent is released from a biocompatible copolymer matrix. In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix for at least about 7 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix for about 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days. In some embodiments, the activator or diagnostic agent is released from the biocompatible copolymer matrix by degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently compressible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently flexible to accommodate injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is ​​sufficiently elastic to recover its original shape after injection with an IOL injector having an injector tip inner diameter of approximately 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is ​​sufficiently elastic so that the ophthalmic article recovers its shape once implanted in the eye. In some embodiments, the ophthalmic article is sufficiently physically stable in the physiological environment so that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in the target eye. In some embodiments, the ophthalmic article contains one or more activators and / or diagnostic agents in an amount of approximately 1 μg to 800 μg.

[0028]

[0028] Further aspects and advantages of the Disclosure will be readily apparent to those skilled in the art from the following detailed description, which shows and describes only exemplary embodiments of the Disclosure. As will be recognized, other and different embodiments of the Disclosure are possible, and some of their details can be modified in various obvious matters without departing from the Disclosure. Accordingly, the drawings and description should be considered as illustrative and not as limiting.

[0029]

[0029] In particular, this specification is intended to supersede and / or take precedence over any such conflicting matters.

[0030] Novel features of the present invention are specifically described in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description illustrating exemplary embodiments utilizing the principles of the present invention, and to the appended drawings (also referred to herein as "Figure" and "FIG."). [Brief explanation of the drawing]

[0030] [Figure 1A]

[0031] Figure 1A illustrates a perspective view of an ophthalmic article according to several embodiments. [Figure 1B]

[0032] Figure 1B illustrates another perspective view of an ophthalmic article according to several embodiments. [Figure 2A]

[0033] Figure 2A illustrates a plan view of an annular ophthalmic article according to several embodiments. [Figure 2B]

[0034] Figure 2B illustrates a cross-sectional view of an annular ophthalmic article according to several embodiments. [Figure 2C]

[0035] Figure 2C illustrates a plan view of a toroidal ophthalmic article according to several embodiments. [Figure 2D]

[0036] Figure 2D illustrates a cross-sectional view of a toroidal ophthalmic article according to several embodiments. [Figure 2E]

[0037] Figure 2E illustrates a plan view of a square-shaped ophthalmic article according to several embodiments. [Figure 2F]

[0038] Figure 2F illustrates a cross-sectional view of a square-shaped ophthalmic article according to several embodiments. [Figure 2G]

[0039] Figure 2G illustrates a plan view of an octagonal ophthalmic article according to several embodiments. [Figure 2H]

[0040] Figure 2H illustrates a cross-sectional view of an octagonal ophthalmic article according to several embodiments. [Figure 3]

[0041] Figure 3A illustrates a plan view of an intraocular lens having an ophthalmic article according to several embodiments.

[0042] Figure 3B illustrates a side view of an intraocular lens (IOL) with an ophthalmic article according to several embodiments. [Figure 4]

[0043] Figure 4A illustrates a plan view of an IOL with an ophthalmic article according to several embodiments.

[0044] Figure 4B illustrates a side view of an IOL with an ophthalmic article according to several embodiments. [Figure 5A]

[0045] Figure 5A schematically illustrates an example of a loading method according to several embodiments. [Figure 5B]

[0046] Figure 5B schematically illustrates an example of an embedding method according to several embodiments. [Figure 5C]

[0047] Figure 5C schematically illustrates another example of an intraocular lens with an ophthalmic article attached to it. [Figure 6]

[0048] Figure 6 schematically illustrates examples of administration, treatment, and / or diagnostic methods according to many embodiments. [Figure 7A]

[0049] Figure 7A illustrates an example of ophthalmic supplies. [Figure 7B]

[0050] Figure 7B illustrates an example of an ophthalmic article found in an ophthalmic device. [Figure 7C]

[0051] Figure 7C illustrates a side view of an exemplary ophthalmic article. [Figure 7D]

[0052] Figure 7D illustrates a plan view of an exemplary ophthalmic article. [Figure 8A]

[0053] Figure 8A illustrates an example of an ophthalmic item located in the haptics of an IOL. [Figure 8B]

[0054] Figure 8B schematically illustrates ophthalmic supplies. [Figure 9A]

[0055] Figure 9A illustrates the forward extension state of an ophthalmic article. [Figure 9B]

[0056] Figure 9B illustrates the stretched state of ophthalmic items. [Figure 9C]

[0057] Figure 9C illustrates the recovery status of ophthalmic items. [Figure 10]

[0058] Figure 10 illustrates the elongation in destructive tests performed on ophthalmic materials. [Figure 11]

[0059] Figure 11 illustrates the stretched state of ophthalmic products. [Figure 12]

[0060] Figure 12 shows an embodiment that is an example of an ophthalmic article. [Figure 13]

[0061] Figure 13 shows another embodiment of an ophthalmic article. [Figure 14A]

[0062] Figure 14A shows an exemplary appearance of an ophthalmic article and IOL before in vitro IOL injection. [Figure 14B]

[0063] Figure 14B shows an exemplary appearance of the ophthalmic article and IOL after in vitro IOL injection. [Figure 15A]

[0064] Figure 15A shows an exemplary appearance of the ophthalmic article and IOL before in vitro IOL injection. [Figure 15B]

[0065] Figure 15B shows an exemplary appearance of the ophthalmic article and IOL after in vitro IOL injection. [Figure 16A]

[0066] Figure 16A shows an exemplary appearance of the ophthalmic article and IOL before in vitro IOL injection. [Figure 16B]

[0067] Figure 16B shows an exemplary appearance of the ophthalmic article and IOL after in vitro IOL injection. [Figure 17A]

[0068] Figure 17A shows an exemplary appearance of the ophthalmic article and IOL before in vitro IOL injection. [Figure 17B]

[0069] Figure 17B shows the appearance of ophthalmic items and the IOL after in vitro IOL injection. [Figure 18]

[0070] Figures 18A, 18C, and 18E show the appearance of coated IOLs before in vitro IOL injection.

[0071] Figures 18B, 18D, and 18F show the appearance of coated IOLs after in vitro IOL injection. [Figure 19]

[0072] Figures 19A, 19C, and 19E show the appearance of coated IOLs before in vitro IOL injection.

[0073] Figures 19B, 19D, and 19F show the appearance of coated IOLs after in vitro IOL injection. [Figure 20A]

[0074] Figures 20A to 20F show examples of qualitative tests for copolymers. [Figure 20B]

[0074] Figures 20A to 20F show examples of qualitative tests of copolymers. [Figure 20C]

[0074] Figures 20A to 20F show examples of qualitative tests of copolymers. [Figure 20D]

[0074] Figures 20A to 20F show examples of qualitative tests of copolymers. [Figure 20E]

[0074] Figures 20A to 20F show examples of qualitative tests of copolymers. [Figure 20F]

[0074] Figures 20A to 20F show examples of qualitative tests of copolymers. [Figure 21A]

[0075] Figures 21A-21E show examples of qualitative tests for other copolymers. [Figure 21B]

[0075] Figures 21A to 21E show examples of qualitative tests for other copolymers. [Figure 21C]

[0075] Figures 21A to 21E show examples of qualitative tests for other copolymers. [Figure 21D]

[0075] Figures 21A to 21E show examples of qualitative tests for other copolymers. [Figure 21E]

[0075] Figures 21A to 21E show examples of qualitative tests for other copolymers. [Figure 22A]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 22B]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 22C]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 22D]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 22E]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 22F]

[0076] Figures 22A to 22F show examples of qualitative tests for other copolymers. [Figure 23A]

[0077] Figures 23A-D show ring-shaped structures made from copolymers. [Figure 23B]

[0077] Figures 23A to D show ring-shaped rings made from copolymer. [Figure 23C]

[0077] Figures 23A to D show ring-shaped rings made from copolymer. [Figure 23D]

[0077] Figures 23A to D show ring-shaped rings made from copolymer. [Figure 24A]

[0078] Figure 24A shows a ring-shaped structure containing the copolymer. [Figure 24B]

[0079] Figure 24B shows the ophthalmic product after it has been extended. [Figure 24C]

[0080] Figure 24C shows the appearance of the polymer ring and IOL before in vitro IOL injection. [Figure 24D]

[0081] Figure 24D shows the state of the ophthalmic product after injection. [Figure 25A]

[0082] Figure 25A shows the cumulative amount of dexamethasone released from ophthalmic articles. [Figure 25B]

[0083] Figure 25B shows the cumulative amount of ketrolac released from ophthalmic articles. [Figure 26]

[0084] Figure 26 shows the cumulative amount of moxifloxacin released from ophthalmic products. [Figure 27]

[0085] Figure 27 illustrates an example of the antibiotic activity of a drug (e.g., moxifloxacin) released from an ophthalmic article. [Figure 28A]

[0086] Figure 28A illustrates the diameters of the inhibition region on days 0, 1, 2, 7, and 9. [Figure 28B]

[0087] Figure 28B illustrates the diameter of the inhibition region on days 0, 1, 2, 7, and 9. [Figure 29]

[0088] Figure 29 shows an example of the location of the IOL in an eye that has undergone cataract surgery. [Figure 30A]

[0089] Figures 30A-30C schematically illustrate a typical surgical implantation procedure. [Figure 30B]

[0089] Figures 30A to 30C schematically illustrate a typical surgical implantation. [Figure 30C]

[0089] Figures 30A to 30C schematically illustrate a typical surgical implantation. [Figure 31]

[0090] Figures 31A–31H illustrate examples of digital planar photographs of rabbit eyes on days 1 and 7. [Figure 32]

[0091] Figure 32 shows the average ophthalmic examination scores on day 0 (baseline), day 1, day 2, day 4, and day 7. [Figure 33]

[0092] Figure 33 shows the mean intraocular pressure measured on days 0 (baseline), 1, 2, 4, and 7. [Figure 34]

[0093] Figure 34 shows the ophthalmic examination scores for the group that received implants containing vehicles or ketrolac. [Figure 35]

[0094] Figure 35 shows the ophthalmic examination scores for the group that received implants containing a vehicle or dexamethasone. [Figure 36-1]

[0095] Figures 36A-F illustrate digital planar photographs associated with eye examinations of rabbits in one group. [Figure 36-2]

[0096] Figures 36G-L illustrate digital planar photographs associated with eye examinations of rabbits in a different group. [Figure 37A]

[0097] Figure 37A shows the mean intraocular pressure measured for each group on days 0, 1, 3, 7, 14, 21, and 29. [Figure 37B]

[0098] Figure 37B shows the mean intraocular pressure measured on days 0, 1, 3, 7, 14, 21, and 29 for another group. [Figure 38]

[0099] Figures 38A–38D show typical images of the histopathological examination portions of animal eyes in the group. [Figure 39]

[0100] Figures 39A–39D show typical images of histopathological examination portions of animal eyes in a different group. [Figure 40]

[0101] Figure 40 illustrates the tissue concentration of ketrolac in aqueous humor. [Figure 41]

[0102] Figure 41 illustrates the tissue concentration of dexamethasone in aqueous humor. [Figure 42]

[0103] Figure 42 illustrates the area under the curve analysis for ketrolac concentration in aqueous humor. [Figure 43]

[0104] Figure 43 illustrates the area under the curve analysis for dexamethasone concentration in aqueous humor. [Figure 44]

[0105] Figure 44 illustrates the mean total ophthalmoscopic examination scores for the treatment groups on days 0, 1, 3, 7, 14, 21, 30, 60, and 90. [Figure 45]

[0106] Figure 45 shows the PCO subscores at 0, 1, 3, 7, 14, 21, 30, 60, and 90 days post-surgery. [Figure 46]

[0107] Figure 46 illustrates the total ophthalmological examination score as assessed using the modified Hackett-McDonald scale. [Figure 47]

[0108] Figure 47 illustrates intraocular pressure measurements at 0, 30, 60, and 90 days post-surgical. [Figure 48]

[0109] Figure 48 illustrates the anterior chamber cell (ACC) score. [Figure 49]

[0110] Figure 49 shows the pain scores for subjects on days 0, 1, 7, and 28. [Figure 50A]

[0111] Figures 50A to 50D illustrate the process of loading an IOL with an attached ophthalmic article into an IOL injector cartridge. [Figure 50B]

[0111] Figures 50A to 50D illustrate the process of loading an IOL with an attached ophthalmic article into an IOL injector cartridge. [Figure 50C]

[0111] Figures 50A to 50D illustrate the process of loading an IOL with an attached ophthalmic article into an IOL injector cartridge. [Figure 50D]

[0111] Figures 50A to 50D illustrate the process of loading an IOL with an attached ophthalmic article into an IOL injector cartridge. [Figure 51]

[0112] Figures 51A-51D illustrate the surgical implantation of an IOL with an attached ophthalmic device into the eye of a human subject. [Figure 52A]

[0113] Figure 52A illustrates a slit lamp photograph of the subject. [Figure 52B]

[0113] Figure 52B illustrates a slit lamp photograph of the subject. [Figure 53]

[0114] Figure 53 illustrates differential scanning calorimetry for ophthalmic articles. [Figure 54]

[0115] Figure 54 illustrates the preserved modulus curve, loss modulus, and tan-delta curve for ophthalmic articles. [Modes for carrying out the invention]

[0031]

[0116] While various embodiments of the present invention are shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided for illustrative purposes only. Numerous variations, modifications, and substitutions can be conceived by those skilled in the art without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be available.

[0032]

[0117] Where used herein, the singular forms "a," "an," and "the" include multiple references unless the context otherwise explicitly indicates. Any reference to "or" herein is intended to include "and / or" unless otherwise stated.

[0033]

[0118] As used herein, “substantial” or “substantially” may refer to an action, feature, characteristic, state, structure, item, or result of a complete or near-complete size or degree. For example, a substantially encompassed object means that the object is either completely or nearly completely encompassed. The exact possible degree of deviation from absolute completion may, in some cases, depend on the specific context. However, to speak of proximity to completion in general gives the impression of having some overall result as if absolute and total completion had been achieved. The use of “substantially” is equally applicable when used in a negative sense to refer to the complete or near-complete absence of an action, feature, characteristic, state, structure, item, or result.

[0034]

[0119] As used herein, “effective amount” refers to the amount of an active ingredient sufficient to achieve the intended composition or physiological effect when present in a composition. “Therapeutic effective amount” therefore refers to the amount of an active ingredient sufficient to achieve a therapeutic outcome that treats or prevents a condition for which the active ingredient is known to be effective, even if the active ingredient is substantially nontoxic. It is understood that various biological factors can affect a substance’s ability to perform its intended task. Therefore, “effective amount” or “therapeutic effective amount” may, in some cases, be determined by such biological factors. Furthermore, while the achievement of a therapeutic effect may be measured by a physician or other limited medical professional using assessments known in the art, it is recognized that individual variations in treatment and response may make the achievement of a therapeutic effect subjective. However, the determination of an effective amount may be within the scope of ordinary skill in the fields of pharmaceuticals and nutrition, as well as in medicine.

[0035]

[0120] As used herein, “reshaping” may mean reducing the overall dimensions of an object (e.g., an ophthalmic article) by, for example, physically or chemically bending, folding, rolling, or otherwise folding the object into a desired arrangement (shape). For that purpose, the terms “folding,” “bending,” “folding,” and “rolling” may mean reshaping an ophthalmic article and / or ophthalmic device of the present invention to enable the ophthalmic article to fit an intraocular syringe tip diameter that is smaller with respect to at least one dimension than that of the ophthalmic article in its original shape (e.g., before reshaping).

[0036]

[0121] As used herein, “Subject” refers to a mammal that can benefit from the administration or method of any of the compositions described herein. Examples of subjects include humans, but may also include other animals, such as horses, pigs, cattle, dogs, cattle, rabbits, or aquatic mammals.

[0037]

[0122] Whenever the terms “at least,” “greater than,” or “greater than or equal to” precede the first number in a set of two or more numbers, the terms “at least,” “greater than,” or “greater than or equal to” apply to each of the numbers in that set. For example, 1, 2, or 3 or more is equal to 1 or more, 2 or more, or 3 or more.

[0038]

[0123] Whenever the terms “maximum,” “not exceeding,” “up to,” “less than,” or “less than or equal to” precede the first number in a set of two or more numbers, the terms “not exceeding,” “less than,” or “less than or equal to” apply to each of the numbers in that set. For example, 3, 2, or 1 or less is equal to 3 or less, 2 or less, or 1 or less.

[0039]

[0124] Cataract surgery has advanced remarkably over the past 30 to 40 years. The emergence of new biomaterials (e.g., flexible acrylic polymers) has enabled the development of deformable elastic IOLs that can be folded, rolled, or otherwise deformed into a narrow shape for injection through small incisions. Advances in surgical instruments (e.g., IOL syringe cartridges and syringes) have improved the efficiency of folding and rolling IOLs with greater consistency and reliability than older methods (e.g., IOL forceps). Such innovations have reduced the invasiveness and duration of cataract surgery, resulting in fewer complications, better refractive outcomes, and faster patient recovery.

[0040]

[0125] When designing ophthalmic articles (e.g., drug delivery devices) intended for implantation in the eye, the physical, chemical, and / or biological properties of the ophthalmic article may affect its safety profile. The ophthalmic article may be sufficiently flexible and / or pliable so as not to deform, abrade, penetrate, obstruct, or otherwise physically injure the internal structures of the eye. Inert materials, including those in drug delivery devices, and some of their degradation products, may be biocompatible and unlikely to cause adverse effects in the eye. Active agents (e.g., active ingredients) and / or diagnostic agents, including those in the ophthalmic article, may be present in amounts sufficient to achieve their intended function, but not exceeding known levels that could cause toxicity in the eye.

[0041]

[0126] Surgical procedures may be optimized to minimize the risk of potential complications and achieve the greatest benefit to the subject (e.g., the patient). Modifications to standard surgical techniques may alter the risk-benefit ratio to the subject (e.g., the patient). When designing ophthalmic articles (e.g., drug delivery devices) to be coupled to ophthalmic devices (e.g., intraocular lenses), the ophthalmic device and the attached ophthalmic articles may conform to standard surgical techniques (e.g., cataract surgery). Furthermore, the aspects of usefulness and human factors of the ophthalmic device and the attached ophthalmic articles may be equivalent to those of the ophthalmic device alone.

[0042]

[0127] This disclosure provides articles, methods, systems, and kits for delivering or administering activators and / or diagnostic agents from an ophthalmic device to the eye. This disclosure also provides articles, methods, systems, and kits for diagnosing and / or treating diseases, conditions, or complications. For example, this disclosure provides articles, methods, devices, systems, and kits for delivering activators (e.g., drugs) from an intraocular lens (IOL) to the eye. In some embodiments, the articles, systems, and associated methods of this disclosure can be positioned within the anterior segment of the eye (e.g., within the lens capsule) to deliver activators and / or diagnostic agents to the posterior segment of the eye. Non-limiting examples of ocular regions found within the posterior segment may include at least one of the vitreous humor, colloid, and retina. In addition to delivery of activators and / or diagnostic agents to the posterior segment, activators and / or diagnostic agents may also be delivered to the anterior segment. The anterior segment may include at least one of the aqueous humor, iris, and lens capsule. The delivery can achieve sustained release of activators and / or diagnostic agents over a period of time (e.g., with continuous release kinetics). Ophthalmic articles for delivering or administering activators and / or diagnostic agents to the eye may include polymer materials (e.g., biocompatible polymer matrices), non-polymer materials, and / or activators (e.g., activators and / or diagnostic agents, various different activators and / or diagnostic agents, or combinations thereof). The ophthalmic articles described herein (e.g., drug delivery devices) can be coupled to ophthalmic devices (e.g., intraocular devices) to achieve delivery of activators and / or diagnostic agents by reducing the number of injections or complex eye drop regimens. This enables automated delivery of activators to the eye and can solve the problem of patient non-compliance.

[0043]

[0128] In some embodiments, the present disclosure provides ophthalmic articles. The ophthalmic articles may include a biocompatible material (e.g., a biocompatible matrix). The biocompatible material may include a polymer material comprising one or more polymers. The polymers may be copolymers derived from one or more monomers. In some embodiments, the polymers may be copolymers derived from a caprolactone monomer and at least one other monomer. In some embodiments, one or more ophthalmic articles may include at least one activator and / or diagnostic agent.

[0044]

[0129] In another embodiment, the Disclosure provides ophthalmic articles. The ophthalmic articles may include a biocompatible material (e.g., a biocompatible matrix). The ophthalmic articles may also include an activator and / or a diagnostic agent. The ophthalmic articles may have elasticity, compressibility, tensile strength, shape recovery, or reformability equivalent to another article containing a biocompatible matrix comprising a copolymer derived from caprolactone monomer and lactide monomer. In some embodiments, the ophthalmic articles may have elasticity, compressibility, tensile strength, shape recovery, or reformability equivalent to an article containing a biocompatible matrix comprising a copolymer derived from about 40% by weight of caprolactone monomer and about 60% by weight of lactide monomer. The ophthalmic articles can be configured to bond to an ophthalmic device portion (e.g., haptics of an intraocular lens).

[0045]

[0130] In another embodiment, the disclosure provides an ophthalmic system. The ophthalmic system may include one or more ophthalmic articles. One or more ophthalmic articles may include a biocompatible material (e.g., a polymer matrix) comprising at least a polymer. The polymer may be a copolymer. The copolymer may be derived from one or more monomers. In some embodiments, one or more monomers may be lactide, glycolide, caprolactone, ethylene glycol, trimethylene carbonate, or a combination thereof. In some embodiments, the polymer may be a copolymer derived from a caprolactone monomer and at least one other monomer. In some embodiments, one or more ophthalmic articles may include at least one activator and / or diagnostic agent. The ophthalmic system may also include one or more ophthalmic devices (e.g., intraocular lenses). One or more ophthalmic devices may be coupled to one or more ophthalmic articles.

[0046]

[0131] In any of the various embodiments, one or more ophthalmic articles described herein are designed in composition, size, shape, and combinations thereof to bring the ophthalmic article as close as possible to the target eye. In some embodiments, one or more ophthalmic articles may include a material. The material may be a biocompatible material (e.g., a biocompatible matrix). The biocompatible matrix may be a polymer matrix. The material may include polymer materials (e.g., polymer matrices) and / or non-polymer materials. Nonpolymer materials may include glass (silica), soda-lime glass, alkali aluminosilicate glass, borosilicate glass, alkali-free glass, crystal glass, quartz glass, metals and metal alloys (steel, aluminum, silver, gold, tantalum, titanium, copper, nickel, platinum-palladium, zinc-tin, antimony, bismuth, zinc, manganese, antimony, molybdenum, vanadium), crystalline materials (diamond, sapphire, graphene), carbon fiber, fiberglass, silicon carbide, alumina, graphite, aluminum oxide, chromium aluminum oxide, brown fused aluminum oxide (ALOX), brown fused aluminum oxide (ALOX) with low titanium dioxide, zirconia-alumina, alumina hydrate, ceramic aluminum oxide (ALOX), green silicon carbide, black silicon carbide, boron carbide, cubic boron nitride, and diamond.

[0047]

[0132] Biocompatible materials may contain substances that do not induce harmful reactions when placed in a biological environment. Biocompatible materials may be of natural or synthetic origin.

[0133] In some embodiments, the polymer material may include biocompatible polymers and / or biodegradable polymers. For example, a polymer material or composition for use in ophthalmic articles may include a material that is ophthalmically compatible (e.g., biocompatible) in such a way that it does not substantially interfere with the function or physiological function of the eye. Such polymer materials may also be biodegradable and / or bioerosive. A biodegradable polymer may refer to one or more polymers that can be eroded or degraded over time (e.g., in vivo) by at least partial contact with substances found in the surrounding tissue fluid under physiological conditions, or by cellular function. The release of activators and / or diagnostic agents may occur simultaneously with or subsequently to the degradation of the biodegradable polymer over time.

[0048]

[0134] In some embodiments, the polymer material may include homopolymers (e.g., polymers containing one type of monomer repeating units), copolymers (e.g., polymers containing two or more types of monomer repeating units), or polymers containing more than two different polymer units. In some embodiments, the polymer material (e.g., polymer matrix) may include a homogeneous mixture of polymers. For example, a homogeneous mixture of polymers may not include a mixture in which one part differs from another (e.g., by raw materials or density). In some embodiments, the polymer material (e.g., polymer matrix) may include a heterogeneous mixture of polymers. In some embodiments, the polymer material may include a mixture of polymers of the same type (e.g., two different polylactic acid polymers) or different types (e.g., polylactic acid polymers combined with polycaprolactone polymers). In some embodiments, the polymer material may include copolymers. In other embodiments, the copolymer may include one or more block copolymers (represented, for example, by PPPP-HHHH; P and H are each illustrated monomer units), alternating copolymers (represented, for example, by PHPHPHPH; P and H are each illustrated monomer units), statistical or random copolymers (represented, for example, by PHPPHPHH; P and H are each illustrated monomer units), star copolymers, brush copolymers, gradient copolymers, or graft copolymers. In some embodiments, the copolymer may be a random copolymer.

[0049]

[0135] In some embodiments, the polymer material is poly(L-lactide-co-caprolactone) (e.g., with various ratios of L-lactide and caprolactone content), poly(D-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly-(D-lactic acid) (PDLA), poly-(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG), poly(glycolic acid) (PGA), poly(L-lactide-co-glycolide), Poly(D-lactide-co-glycolide), poly(D,L-lactide-co-glycolide) (PLGA), poly(L-lactide-co-trimethylene carbonate), poly(D-lactide-co-trimethylene carbonate), poly(D,L-lactide-co-trimethylene carbonate), poly(trimethylene carbonate-co-ε-caprolactone), poly(caprolactone-co-glycolide), polyorthoester, polyanhydride, polyester, polyamide, polyesteramide, polycarbonate, polyethylene, polypropylene, polygalactoic acid (polygalactic acid) (poly(ricenolic acid), polyacrylamide, polystyrene, polyurethane, silicone, hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyglycolic acid-polyvinyl alcohol copolymer, polycaprolactone-polyethylene glycol copolymer, collagen, croscarmellose collagen, hyaluronic acid, elastin, polyhydroxybutyrate, polyalkane anhydride, gelatin, cellulose, oxidized cellulose, polyphosphazene, poly(sebacic acid), poly(ricinoleic acid) (acid), poly(fumaric acid), chitin, chitosan, polyvinylpyrrolidone (PVP), synthetic cellulose esters, polyacrylic acid, polybutyric acid; triblock copolymers (e.g., PLGA-PEG-PLGA, PEG-PLGA-PEG), poly(N-isopropylacrylamide), poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer (PEO-PPO-PEO), polyvaleric acid, poly(valerolactone), polyhydroxyalkylcellulose; siloxanes, polysiloxanes;Dimethylsiloxane / methylvinylsiloxane copolymer; poly(dimethylsiloxane / methylvinylsiloxane / methylhydrogensiloxane)dimethylvinyl or trimethyl copolymer, polypeptide, poly(amino acid), poly(dioxanone), poly(alkylene alkylate), hydrophobic polyether, polyether ester, polyacetal, polycyanoacrylate, polyacrylate, polymethyl methacrylate, polysiloxane, poly(oxyethylene) / poly(oxypropylene) copolymer, polyketal, polyphosphate, polyhydroxyvalerate, polyalkylene oxalate, polyalkylene succinate, poly(maleic acid), and copolymers thereof, or derivatives thereof, including oxidized, reduced, monosubstituted, disubstituted, polysubstituted derivatives, or any combination thereof. In some embodiments, the polymer material may contain one or more elements described, for example, by Abraham J. Domb et al., Biodegradable Polymers in Clinical Use and Clinical Development (2011), (ISBN: 978-1-118-01580-3), which are incorporated herein by reference in whole. In some embodiments, the polymer material may contain polymers (e.g., polylactic acid, polycaprolactone, poly(lactide-co-caprolactone) and / or poly(L-lactide-co-caprolactone)) that enable the sustained release of activators and / or diagnostic agents to the eye over time. In some embodiments, the polymer material may contain polylactic acid. In other embodiments, the polymer material may contain polycaprolactone. In other embodiments, the polymer material may contain poly(lactide-co-caprolactone). In other embodiments, the polymer material may contain poly(L-lactide-co-caprolactone).

[0050]

[0136] In some embodiments, the polymer material comprises a copolymer and a mixture of another homopolymer or another copolymer. In some embodiments, the polymer may comprise a mixture of poly(lactide-co-caprolactone) (PLCL) and another homopolymer or another copolymer. In some embodiments, the polymer may comprise a mixture of poly(L-lactide-co-caprolactone) and another homopolymer or another copolymer. In some embodiments, the polymer may comprise a mixture of poly(L-lactide-co-caprolactone) and PLA. In some embodiments, the polymer may comprise a mixture of poly(L-lactide-co-caprolactone) and PGA. In some embodiments, the polymer may comprise a mixture of poly(L-lactide-co-caprolactone) and PLGA. In some embodiments, the polymer may comprise a mixture of poly(L-lactide-co-caprolactone) and PGA and / or PLGA.

[0051]

[0137] In some embodiments, examples of polymer materials include materials derived from and / or containing organic esters and / or organic ethers that, when decomposed, result in physiologically acceptable decomposition products. In some embodiments, polymer materials may include materials derived from and / or containing anhydrides, amides, esters, orthoesters, etc., either alone or in combination with other monomers. Polymer materials may be addition or condensation polymers. Polymer materials may be crosslinked or uncrosslinked.

[0052]

[0138] In some embodiments, in addition to carbon and hydrogen, the polymer may contain at least one of oxygen and / or nitrogen. Oxygen may exist as oxy (e.g., hydroxy or ether), carbonyl (e.g., non-oxocarbonyl, carboxylic acid, carboxylic acid ester, amide). Nitrogen may exist as part of an amide, cyano, or amino (including substituted amino) moiety. In some embodiments, polymers of hydroxyaliphatic carboxylic acids, polymers, homopolymers or copolymers of hydroxyalkanoates, and polysaccharides can be used in ophthalmic articles. In some embodiments, polyesters can also be used in ophthalmic articles and may include polymers of D-lactic acid, L-lactic acid, racemic lactic acid (D,L-lactic acid), caproic acid, hydroxybutyric acid, glycolic acid, caprolactone, valerolactone, polymers and copolymers thereof in certain ratios, or combinations thereof.

[0053]

[0139] Some properties of polymers or polymer materials for use in embodiments of this disclosure may include biocompatibility, compatibility with activators and / or diagnostic agents, ease of use of the polymer in creating activator and / or diagnostic agent delivery systems described herein, desirable half-life in physiological environments, and hydrophilicity.

[0054]

[0140] In some embodiments, the polymer matrix used in the manufacture of ophthalmic articles may be a synthetic aliphatic polyester, for example, a polymer of lactic acid and / or caproic acid, which may include poly-(D,L-lactide)(PLA), poly-(D-lactide), poly-(L-lactide), polycaprolactone (PCL), poly(L-lactide-co-caprolactone), poly(D-lactide-co-caprolactone), or mixtures or copolymers thereof.

[0055]

[0141] These polymers can decompose via hydrolysis of the main chain (bulk erosion), and the final degradation products of PLCL are lactic acid (e.g., L-lactic acid) and caproic acid, which are non-toxic and considered natural metabolites. Lactic acid (e.g., L-lactic acid) and caproic acid are safely removed by conversion to carbon dioxide and water via the Krebs cycle. Ophthalmic articles and / or biocompatible materials can decompose homogeneously at a constant rate throughout the polymer matrix (e.g., non-enzymatic hydrolysis of its ester bonds throughout the polymer matrix in the presence of water in the surrounding tissue), thereby allowing the diffusion of activators and / or diagnostic agents from the matrix into the surrounding environment. This is in contrast to other polymer drug release systems that decompose through "surface erosion," where polymer degradation occurs only on the outer exposed surface.

[0056]

[0142] In bulk erosion, matrix degradation occurs throughout the matrix simultaneously with the solubilization of oligomers in the surrounding medium, and drug release occurs by diffusion, a concentration-dependent phenomenon. Surface erosion, on the other hand, originates from the front of the device and continuously moves towards the device core. If these types of polymers are composed of highly hydrophobic monomers, the monomers do not allow aqueous media to penetrate the core, and furthermore, oligomers usually accumulate on the device itself, further hindering the release of encapsulated bioactive substances. When a certain volume of the device is exposed to the environment, release occurs in a zero-order manner. These surface-eroding polymers have highly unstable hydrolytic bonds and may not be suitable for sustained release on nanoscopic supports.

[0057]

[0143] In some embodiments, poly(lactide-co-caprolactone) (PLCL) can be synthesized through random ring-opening copolymerization of D,L-lactide and ε-caprolactone. Sequential monomer units of D,L-lactide or ε-caprolactone can be linked together by ester bonds. The ratio of lactide to caprolactone can be varied to alter the biodegradability of the product. By changing the ratio, the polymer degradation time can be adjusted. Drug release properties may be influenced by the biodegradation rate, molecular weight or molecular mass, and crystallinity in the drug delivery system. By modifying and customizing the biodegradable polymer matrix, the drug delivery profile can be altered.

[0058]

[0144] In some embodiments, poly(L-lactide-co-caprolactone) can be synthesized through random ring-opening copolymerization of L-lactide and ε-caprolactone. Sequential monomer units of L-lactide or ε-caprolactone are linked together by ester bonds. The ratio of L-lactide to ε-caprolactone can be varied to alter the biodegradability of the product. By changing the ratio, the polymer degradation time can be adjusted. Drug release properties may be influenced by the biodegradation rate, molecular weight or molecular mass, and crystallinity in the drug delivery system. By modifying and customizing the biodegradable polymer matrix, the drug delivery profile can be altered.

[0059]

[0145] Alternatively, the synthesis of PLCLs of various molecular weights or masses with various D,L-lactide-caprolactone ratios can be carried out. For example, the synthesis of poly(L-lactide-co-caprolactone) of various molecular weights or masses with various L-lactide-caprolactone ratios is possible. The polymers used to form the ophthalmic articles of this disclosure have related independent properties that, when combined, exhibit the properties necessary to achieve a sustained release of an effective amount (e.g., a therapeutically effective amount) of activators and / or diagnostic agents. Some of the main polymer properties that control the activator and / or diagnostic agent release rate may be the molecular weight distribution or molecular mass distribution, the ratio of polymer end groups (i.e., carboxylic acids or esters) and monomers in the copolymer, and / or the ratio of polymers and / or copolymers in the polymer matrix. This disclosure provides examples of polymer matrices possessing desirable activator and / or diagnostic agent release properties by manipulating one or more of the aforementioned properties to develop suitable ophthalmic articles.

[0060]

[0146] Some polymer materials can be prone to enzyme instability or hydrolysis instability. Water-soluble polymers can be crosslinked with hydrolysis or biodegradation-instability crosslinks to produce useful water-insoluble polymers. Therefore, stability can vary depending on the selection of one or more monomers, regardless of whether homopolymers or copolymers using mixtures of polymers are used, and regardless of whether the polymer contains terminal acidic groups.

[0061]

[0147] Another factor controlling the biodegradation of the polymer matrix, and consequently the extended release profile of the ophthalmic article, is the relative average molecular weight or molecular mass of the polymer composition used in the ophthalmic article. Various molecular weights or molecular masses of the same or different polymer compositions can modulate the release profile (e.g., long-term release, non-extended release, linear release) of at least one activator and / or diagnostic agent. In some embodiments, the polymer material may be selected from the biodegradable polymers disclosed herein that do not swell substantially in the presence of aqueous humor. For example, PLGA polymers swell when used as matrix materials for drug delivery implants, while PLA-based polymer blends do not swell significantly in the presence of aqueous humor.

[0062]

[0148] Examples of polymers used in various embodiments of this disclosure include 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 54:46, 53:47, 52:48, 51:49, 60:40, 61:39, 62:38, 63:37, 64:35, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:2 The molar ratios of the first monomer (e.g., L-lactide) to the second monomer (e.g., ε-caprolactone) may include, but are not limited to, 6, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18, 83:17, 84:16, 85:15, 90:10, or 95:5, and may include variations in the molar ratio of the first monomer (e.g., L-lactide) to the second monomer between approximately 50:50 and approximately 85:15. In some embodiments, the molar ratio of the first monomer (e.g., L-lactide) to the second monomer may be any ratio other than 50:50 (e.g., ε-caprolactone). In some embodiments, the molar ratio of the first monomer (e.g., L-lactide) to the second monomer (e.g., ε-caprolactone) may be 60:40.

[0063]

[0149] Examples of polymers used in various embodiments of this disclosure include approximately 5:95, approximately 10:90, approximately 15:85, approximately 20:80, approximately 25:75, approximately 30:70, approximately 35:65, approximately 40:60, approximately 45:55, approximately 50:50, approximately 51:49, approximately 52:48, approximately 53:47, approximately 54:46, approximately 55:45, approximately 54:46, approximately 53:47, approximately 52:48, approximately 51:49, approximately 60:40, approximately 61:39, approximately 62:38, approximately 63:37, approximately 64:35, approximately 65:35, approximately 66:34, approximately 67:33, approximately 68:32, approximately 69: 31, including but not limited to weight ratios of a first monomer (e.g., L-lactide) to a second monomer (e.g., ε-caprolactone) ranging from approximately 50:50 to approximately 85:15, including, but not limited to, approximately 70:30, approximately 71:29, approximately 72:28, approximately 73:27, approximately 74:26, approximately 75:25, approximately 76:24, approximately 77:23, approximately 78:22, approximately 79:21, approximately 80:20, approximately 81:19, approximately 82:18, approximately 83:17, approximately 84:16, approximately 85:15, approximately 90:10, or approximately 90:15. In some embodiments, the ratio of the first monomer (e.g., L-lactide) to the second monomer may be any ratio other than 50:50. In some embodiments, the molar ratio of the first monomer (e.g., L-lactide) to the second monomer (e.g., ε-caprolactone) may be 60:40.

[0064]

[0150] In one example, the polymer material may include poly(lactide-co-caprolactone) having a copolymer ratio of 10:90 to 90:10, and in another case, 52:48 to 90:10. In yet another example, the copolymer ratio may be about 60:40 to about 40:60, or about 55:45 to about 45:55. In some embodiments, the copolymer ratio may be about 60:40. In some embodiments, the copolymer ratio may be about 50:50. In some embodiments, the copolymer ratio may be a ratio other than about 50:50. In some embodiments, the copolymer ratio may be 52 to 78:48 to 22, and in another specific example, 60 to 90:40 to 10.

[0065]

[0151] In one example, the polymer material may include poly(L-lactide-co-caprolactone) having a copolymer ratio of 10:90 to 90:10, and in another case, 52:48 to 90:10. In yet another example, the copolymer ratio may be about 60:40 to about 40:60, or about 55:45 to about 45:55. In some embodiments, the copolymer ratio may be about 60:40. In some embodiments, the copolymer ratio may be about 50:50. In some embodiments, the copolymer ratio may be a ratio other than about 50:50. In some embodiments, the copolymer ratio may be 52 to 78:48 to 22, and in another specific example, 60 to 90:40 to 10. The degradation rate may be determined by such ratios, but additional alternative approaches may also be useful, for example, in device coatings and particle encapsulation.

[0066]

[0152] In one example, the polymer material may include poly(L-lactide-co-caprolactone) having a copolymer ratio of 10:90 to 90:10, and in another case, 52:48 to 90:10. In yet another example, the copolymer ratio may be about 60:40 to about 40:60, or about 55:45 to about 45:55. In some embodiments, the copolymer ratio may be about 60:40. In some embodiments, the copolymer ratio may be about 50:50. In some embodiments, the copolymer ratio may be a ratio other than about 50:50. In some embodiments, the copolymer ratio may be 52 to 78:48 to 22, and in another specific example, 60 to 90:40 to 10.

[0067]

[0153] In some embodiments, the polymer material (e.g., a biocompatible copolymer matrix) may be derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of at least one other monomer. In some embodiments, the polymer material (e.g., a biocompatible copolymer matrix) may be derived from about 40% by weight of caprolactone monomer and about 60% by weight of at least one other monomer. In some embodiments, the at least one other monomer may be lactide, glycolide, caprolactone, ethylene glycol, trimethylene carbonate, or a combination thereof. In some embodiments, the at least one other monomer is lactide.

[0068]

[0154] In some embodiments, the polymer material (e.g., a biocompatible matrix) may be derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of lactide.

[0069]

[0155] In some embodiments, the polymer material (e.g., biocompatible matrix) may be derived from about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of L-lactide.

[0070]

[0156] In some embodiments, the ophthalmic article may contain at least about 50% by weight of polymer material, and / or at least about 50% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 55% by weight of polymer material, and / or at least about 45% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 60% by weight of polymer material, and / or at least about 40% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 65% by weight of polymer material, and / or at least about 35% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 70% by weight of polymer material, and / or at least about 30% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 75% by weight of polymer material, and / or at least about 25% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 80% by weight of polymer material and / or at least about 20% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 85% by weight of polymer material and / or at least about 15% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 90% by weight of polymer material and / or at least about 10% by weight of an activator and / or diagnostic agent. In some embodiments, the ophthalmic article may contain at least about 95% by weight of polymer material and / or at least about 5% by weight of an activator and / or diagnostic agent.

[0071]

[0157] In some embodiments, the ophthalmic article may contain up to about 50% by weight of polymer material, and / or up to about 50% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 55% by weight of polymer material, and / or up to about 45% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 60% by weight of polymer material, and / or up to about 40% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 65% by weight of polymer material, and / or up to about 35% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 70% by weight of polymer material, and / or up to about 30% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 75% by weight of polymer material and / or up to about 25% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 80% by weight of polymer material and / or up to about 20% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 85% by weight of polymer material and / or up to about 15% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 90% by weight of polymer material and / or up to about 10% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain up to about 95% by weight of polymer material and / or up to about 5% by weight of activators and / or diagnostic agents.

[0072]

[0158] In some embodiments, the ophthalmic article may contain about 50% to about 55% by weight of polymer material, and / or about 45% to about 50% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 55% to about 60% by weight of polymer material, and / or about 40% to about 45% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 60% to about 65% by weight of polymer material, and / or about 35% to about 40% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 65% to about 70% by weight of polymer material, and / or about 30% to about 35% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 70% to about 75% by weight of polymer material, and / or about 25% to about 30% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 75% to about 80% by weight of polymer material, and / or about 20% to about 25% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 80% to about 85% by weight of polymer material, and / or about 15% to about 20% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 85% to about 90% by weight of polymer material, and / or about 10% to about 15% by weight of activators and / or diagnostic agents. In some embodiments, the ophthalmic article may contain about 90% to about 95% by weight of polymer material, and / or about 5% to about 10% by weight of activators and / or diagnostic agents.

[0073]

[0159] In some embodiments, the ophthalmic article may contain at least about 50% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 40% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 55% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 35% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 60% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 30% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 65% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 25% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 70% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 20% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 75% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 15% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 80% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 10% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 85% by weight of polymer material, at least about 10% by weight of an activator and / or diagnostic agent, and / or at least about 5% by weight of a pharmaceutically acceptable excipient.

[0074]

[0160] In some embodiments, the ophthalmic article may contain at least about 50% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 30% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 55% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 25% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 60% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 20% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 65% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 15% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 70% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 10% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain at least about 75% by weight of polymer material, at least about 20% by weight of an activator and / or diagnostic agent, and / or at least about 5% by weight of a pharmaceutically acceptable excipient.

[0075]

[0161] In some embodiments, the ophthalmic article may contain up to about 50% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 40% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 55% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 35% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 60% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 30% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 65% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 25% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 70% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 20% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 75% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 15% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 80% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 10% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 85% by weight of polymer material, up to about 10% by weight of an activator and / or diagnostic agent, and / or up to about 5% by weight of a pharmaceutically acceptable excipient.

[0076]

[0162] In some embodiments, the ophthalmic article may contain up to about 50% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 30% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 55% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 25% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 60% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 20% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 65% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 15% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 70% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 10% by weight of a pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article may contain up to about 75% by weight of polymer material, up to about 20% by weight of an activator and / or diagnostic agent, and / or up to about 5% by weight of a pharmaceutically acceptable excipient.

[0077]

[0163] In some embodiments, at least the first monomer (e.g., the first monomer) is present in an amount of about 5% to about 95% by weight, or about 5% to about 90% by weight, or about 5% to about 85% by weight, or about 5% to about 75% by weight, or about 5% to about 70% by weight, or about 5% to about 65% by weight, or about 5% to about 60% by weight, or about 5% to about 55% by weight, or about 5% to about 50% by weight, or about 5% to about 45% by weight, or about 5% to about 40% by weight, or about 5% to about 35% by weight, or about 5% to about 30% by weight, or about 5% to about 25% by weight, or about 5% to about 20% by weight, or about 5% to about 15% by weight. Alternatively, it may be present in ophthalmic articles at concentrations of approximately 5% to 10% by weight, or approximately 10% to 90% by weight, or approximately 10% to 85% by weight, or approximately 10% to 75% by weight, or approximately 10% to 70%, or approximately 10% to a maximum of approximately 65% ​​by weight, or approximately 10% to a maximum of approximately 60%, or approximately 10% to 55%, or approximately 10% to 50%, or approximately 10% to 45%, or approximately 10% to 40%, or approximately 10% to 35%, or approximately 10% to 30%, or approximately 10% to 25%, or 10% to 20%, or approximately 10% to 15% by weight.

[0078]

[0164] In some embodiments, at least the second monomer (e.g., the second monomer) is present in a quantity of about 5% to about 95% by weight, or about 5% to about 90% by weight, or about 5% to about 85% by weight, or about 5% to about 75% by weight, or about 5% to about 70% by weight, or about 5% to about 65% by weight, or about 5% to about 60% by weight, or about 5% to about 55% by weight, or about 5% to about 50% by weight, or about 5% to about 45% by weight, or about 5% to about 40% by weight, or about 5% to about 35% by weight, or about 5% to about 30% by weight, or about 5% to about 25% by weight, or about 5% to about 20% by weight, or about 5% to about 15% by weight It may be present in ophthalmic articles at concentrations of %, or approximately 5% to 10% by weight, or approximately 10% to 90% by weight, or approximately 10% to 85% by weight, or approximately 10% to 75% by weight, or approximately 10% to 70% by weight, or approximately 10% to 65% by weight, or approximately 10% to 60% by weight, or approximately 10% to 55% by weight, or approximately 10% to 50% by weight, or approximately 10% to 45% by weight, or approximately 10% to 40% by weight, or approximately 10% to 35% by weight, or approximately 10% to 30% by weight, or approximately 10% to 25% by weight, or approximately 10% to 20% by weight, or approximately 10% to 15% by weight.

[0079]

[0165] Molecular weight (e.g., polymer molecular weight) or molecular mass can be determined by various means, such as number-average molecular weight (M n ) or molecular mass, weight-average molecular weight (M w ) or molecular mass, viscosity-average molecular weight (Mv) or molecular mass, and / or higher average molecular weight (M z Mz +1 ) or can be expressed in terms of molecular weight or molecular mass. The molecular weight or molecular mass can be measured by any method known in the art. For example, the average molecular weight or molecular mass can be measured by end-group analysis (M n In another embodiment, the average molecular weight or molecular mass may be determined by boiling point elevation (boiling point elevation) or freezing point depression (freezing point depression (M n)。In another embodiment, the average molecular weight or molecular mass can be determined by osmotic pressure measurement (M n )。In another embodiment, the average molecular weight or molecular mass can be determined by gel permeation chromatography (GPC). In another embodiment, the average molecular weight or molecular mass can be determined by light scattering techniques (M w )。In another embodiment, the average molecular weight or molecular mass can be determined by sedimentation equilibrium (Mw, Mz). In another embodiment, the average molecular weight or molecular mass can be determined by viscometry (Mη).

[0080]

[0166] In some embodiments, the active agent and / or drug release profile can be controlled by varying the molecular weight or molecular mass of the material of the ophthalmic article (e.g., PLCL). For example, poly(lactide-co-caprolactone) (PLCL-co-caprolactone) can have an average molecular weight or molecular mass of 1 kilodalton (kDa) to 200 kDa. In some embodiments, the material of the ophthalmic article can include poly(lactide-co-caprolactone) (50:50) having a number average molecular weight (M n ) or molecular mass of about 75 kDa to about 85 kDa. In some embodiments, the material of the ophthalmic article can include poly(lactide-co-caprolactone) (60:40) having a number average molecular weight (M n ) or molecular mass of about 75 kDa to 85 kDa. In some embodiments, the material of the ophthalmic article can include poly(lactide-co-caprolactone) (50:50) having a weight average molecular weight (M w ) or molecular mass of about 75 kDa to about 85 kDa. In some embodiments, the material of the ophthalmic article can include poly(lactide-co-caprolactone) (60:40) having a weight average molecular weight (M w ) or molecular mass of about 75 kDa to 85 kDa.

[0081]

[0167] In some embodiments, the activator and / or drug release profile can be controlled by varying the molecular weight or molecular mass of the material of the ophthalmic article, which is exemplary poly(L-lactide-co-caprolactone). For example, poly(L-lactide-co-caprolactone) may have an average molecular weight or molecular mass of 1 kilodalton (kDa) to 200 kDa. In some embodiments, the material of the ophthalmic article has a number average molecular weight (M) of about 75 kDa to about 85 kDa. n ) or poly(L-lactide-co-caprolactone) (50:50) having a molecular weight. In some embodiments, the material for the ophthalmic article has a number average molecular weight (M) of about 75 kDa to 85 kDa. n ) or poly(L-lactide-co-caprolactone) (60:40) having a molecular weight. In some embodiments, the material for the ophthalmic article has a weight-average molecular weight (M) of about 75 kDa to about 85 kDa. w ) or poly(L-lactide-co-caprolactone) (50:50) having a molecular weight. In some embodiments, the material for the ophthalmic article has a weight-average molecular weight (M) of about 75 kDa to 85 kDa. w ) or may contain poly(L-lactide-co-caprolactone) (60:40) having a molecular weight.

[0082]

[0168] In some cases, the materials for ophthalmic articles must be at least about 1 kDa, at least about 2 kDa, at least about 3 kDa, at least about 4 kDa, at least about 5 kDa, at least about 6 kDa, at least about 7 kDa, at least about 8 kDa, at least about 9 kDa, at least about 10 kDa, at least about 11 kDa, at least about 12 kDa, at least about 13 kDa, at least about 14 kDa, at least about 15 kDa, at least about 16 kDa, at least about 17 kDa, at least about 18 kDa, at least about 19 kDa, at least about 2 0kDa, at least about 21kDa, at least about 22kDa, at least about 23kDa, at least about 24kDa, at least about 25kDa, at least about 26kDa, at least about 27kDa, at least about 28kDa, at least about 29kDa, at least about 30kDa, at least about 31kDa, at least about 32kDa, at least about 33kDa, at least about 34kDa, at least about 35kDa, at least about 36kDa, at least about 37kDa, at least about 38kDa, at least about 39kDa, at least about 40kDa, At least approximately 41kDa, at least approximately 42kDa, at least approximately 43kDa, at least approximately 44kDa, at least approximately 45kDa, at least approximately 46kDa, at least approximately 47kDa, at least approximately 48kDa, at least approximately 49kDa, at least approximately 50kDa, at least approximately 51kDa, at least approximately 52kDa, at least approximately 53kDa, at least approximately 54kDa, at least approximately 55kDa, at least approximately 56kDa, at least approximately 57kDa, at least approximately 58kDa, at least approximately 59kDa, at least approximately 60kDa, at least approximately 6 5kDa, at least about 70kDa, at least about 75kDa, at least about 80kDa, at least about 85kDa, at least about 90kDa, at least about 95kDa, at least about 100kDa, at least about 110kDa, at least about 120kDa, at least about 130kDa, at least about 140kDa, at least about 150kDa, at least about 160kDa, at least about 170kDa, at least about 180kDa, at least about 190kDa, at least about 200kDa, at least about 250kDa, at least about 300kDa,It may have an average molecular weight or average molecular mass (e.g., number-average molecular mass) of at least about 350 kDa or at least about 400 kDa. In either of the above options, the molecular weight or molecular mass may be determined by any of the methods described herein.

[0083]

[0169] In some embodiments, the material of the ophthalmic article is at most about 1 kDa, at most about 2 kDa, at most about 3 kDa, at most about 4 kDa, at most about 5 kDa, at most about 6 kDa, at most about 7 kDa, at most about 8 kDa, at most about 9 kDa, at most about 10 kDa, at most about 11 kDa, at most about 12 kDa, at most about 13 kDa, at most about 14 kDa, at most about 15 kDa, at most about 16 kDa, at most about 17 kDa, at most about 18 kDa, at most about 19 kDa, at most about 20 kDa, and at most about 21 kDa. a, at most approximately 22kDa, at most approximately 23kDa, at most approximately 24kDa, at most approximately 25kDa, at most approximately 26kDa, at most approximately 27kDa, at most approximately 28kDa, at most approximately 29kDa, at most approximately 30kDa, at most approximately 31kDa, at most approximately 32kDa, at most approximately 33kDa, at most approximately 34kDa, at most approximately 35kDa, at most approximately 36kDa, at most approximately 37kDa, at most approximately 38kDa, at most approximately 39kDa, at most approximately 40kDa, at most approximately 41kDa, at most approximately 42kDa, at most approximately 43k Da, maximum approximately 44kDa, maximum approximately 45kDa, maximum approximately 46kDa, maximum approximately 47kDa, maximum approximately 48kDa, maximum approximately 49kDa, maximum approximately 50kDa, maximum approximately 51kDa, maximum approximately 52kDa, maximum approximately 53kDa, maximum approximately 54kDa, maximum approximately 55kDa, maximum approximately 56kDa, maximum approximately 57kDa, maximum approximately 58kDa, maximum approximately 59kDa, maximum approximately 60kDa, maximum approximately 65kDa, maximum approximately 70kDa, maximum approximately 75kDa, maximum approximately 80kDa, maximum approximately 8 It may have an average molecular weight or average molecular mass (e.g., number-average molecular mass) of 5 kDa, at most about 90 kDa, at most about 95 kDa, at most about 100 kDa, at most about 110 kDa, at most about 120 kDa, at most about 130 kDa, at most about 140 kDa, at most about 150 kDa, at most about 160 kDa, at most about 170 kDa, at most about 180 kDa, at most about 190 kDa, at most about 200 kDa, at most about 250 kDa, at most about 300 kDa, at most about 350 kDa, or at most about 400 kDa.In any of the above options, the molecular weight or molecular mass may be determined by any of the methods described herein.

[0084]

[0170] For some accessories, the materials for ophthalmic articles are approximately 1kDa, 2kDa, 3kDa, 4kDa, 5kDa, 6kDa, 7kDa, 8kDa, 9kDa, 10kDa, 11kDa, 12kDa, 13kDa, 14kDa, 15kDa, 16kDa, 17kDa, 18kDa, 19kDa, 20kDa, 21kDa, About 22kDa, about 23kDa, about 24kDa, about 25kDa, about 26kDa, about 27kDa, about 28kDa, about 29kDa, about 30kDa, about 31kDa, about 32kDa, about 3 3kDa, about 34kDa, about 35kDa, about 36kDa, about 37kDa, about 38kDa, about 39kDa, about 40kDa, about 41kDa, about 42kDa, about 43kDa, about 44kD a, approximately 45kDa, approximately 46kDa, approximately 47kDa, approximately 48kDa, approximately 49kDa, approximately 50kDa, approximately 51kDa, approximately 52kDa, approximately 53kDa, approximately 54kDa, approximately 55kDa, approximately 56kDa, approximately 57kDa, approximately 58kDa, approximately 59kDa, approximately 60kDa, approximately 65kDa, approximately 70kDa, approximately 75kDa, approximately 80kDa, approximately 85kDa, approximately 90kDa, approximately 9 It may have an average molecular weight or average molecular mass (e.g., number-average molecular mass) of 5 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 160 kDa, about 170 kDa, about 180 kDa, about 190 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 350 kDa, or about 400 kDa. In any of the above options, the molecular weight or molecular mass may be determined by any of the methods described herein.

[0085]

[0171] In some embodiments, the material of the ophthalmic article may have an average molecular weight or average molecular mass of about 50 kDa to about 400 kDa. In some embodiments, the material of the ophthalmic article may have an average molecular weight or average molecular mass of about 50 kDa to about 55 kDa, about 50 kDa to about 60 kDa, about 50 kDa to about 80 kDa, about 50 kDa to about 100 kDa, about 50 kDa to about 120 kDa, about 50 kDa to about 150 kDa, about 50 kDa to about 200 kDa, about 50 kDa to about 300 kDa, about 50 kDa to about 400 kDa, about 55 kDa to about 60 kDa, about 55 kDa to about 80 kDa, 55kDa to approximately 100kDa, approximately 55kDa to approximately 120kDa, approximately 55kDa to approximately 150kDa, approximately 55kDa to approximately 200kDa, approximately 55kDa to approximately 300kDa, approximately 55kDa to approximately 400kDa, approximately 60kDa to approximately 80kDa, approximately 60kDa to approximately 100kDa, approximately 60kDa to approximately 120kDa, approximately 60kDa to approximately 150kDa, approximately 60kDa to approximately 200kDa, approximately 60kDa to approximately 300kDa, approximately 60k Da ~ about 400kDa, about 80kDa - about 100kDa, about 80kDa - about 120kDa, about 80kDa - about 150kDa, about 80kDa - about 200kDa, about 80kDa - about 300kDa, about 80kD a ~ about 400kDa, about 100kDa - about 120kDa, about 100kDa - about 150kDa, about 100kDa - about 200kDa, about 100kDa - about 300kDa, about 100kDa - about 400kDa, about It may have a number-average molecular weight or average molecular mass of 120kDa to approximately 150kDa, approximately 120kDa to approximately 200kDa, approximately 120kDa to approximately 300kDa, approximately 120kDa to approximately 400kDa, approximately 150kDa to approximately 200kDa, approximately 150kDa to approximately 300kDa, approximately 150kDa to approximately 400kDa, approximately 200kDa to approximately 300kDa, approximately 200kDa to approximately 400kDa, or approximately 300kDa to approximately 400kDa.

[0086]

[0172] In some embodiments, an ophthalmic article may contain one or more activators and / or diagnostic agents in an effective amount (e.g., a therapeutically effective amount) or effective dose (e.g., a therapeutically effective dose) of one or more activators and / or diagnostic agents in an amount that delivers from the lens capsule to the eye (e.g., the posterior segment). The effective amount or effective dose may vary depending on the specific activator and / or diagnostic agent used in the polymer material (e.g., a biodegradable polymer matrix). Furthermore, the effective amount or effective dose may vary depending on the severity of the condition or complication being treated. However, the activators and / or diagnostic agents may be present in an amount that facilitates the delivery of the activators and / or diagnostic agents (e.g., from the anterior segment to the posterior segment (e.g., from the lens capsule)).

[0087]

[0173] In any of the various embodiments of this disclosure, at least one activator and / or diagnostic agent described herein (e.g., found in the Orange Book published by the Food and Drug Administration) for use in various embodiments of this disclosure may be used for the diagnosis and / or treatment or prevention of infections, inflammation (e.g., postoperative inflammation), macular edema, neovascularization, age-related macular degeneration (neovascular or atrophic), glaucoma, diabetic retinopathy, retinopathy of prematurity, uveitis, corneal transplant rejection, fibrosis (e.g., capsular fibrosis), posterior capsule opacity, retinal vein occlusion, infections, etc. For example, an ophthalmic article for delivering or administering an activator to the eye may contain an active ingredient for treating or preventing complications associated with cataract surgery. The function of the activator (e.g., active ingredient) may be to impart pharmacological properties when released from the ophthalmic article. The activator may be an agent or substance having a specific or selected physiological activity that can be measured when administered to a subject in a significant or effective amount. The activator may be a therapeutic agent. Diagnostic agents can be substances used to examine the body in order to detect impairments in the normal functioning of the body. In some cases, diagnostic agents can be pharmacological and non-pharmacological agents that have a functional purpose for use in detecting, for example, ocular malformations, diseases, and aspects of pathophysiology. For example, diagnostic agents can be important and effective diagnostic adjuvants that aid in the visualization of ocular tissue, such as dyes (e.g., fluorescein dye, indocyanine green, trypan blue, dark quencher, cyanine dyes, azo dyes, acridine, fluoron, oxazine, phenanthridine, naphthalimide, rhodamine, benzopyrone, perylene, benzantrone, and benzoxantrone). Diagnostic agents may include paramagnetic molecules, fluorescent compounds, magnetic molecules, radionuclides, X-ray imaging agents, and / or contrast agents. In some embodiments, diagnostic agents are radiopharmaceuticals, contrast agents for use in imaging techniques, allergen extracts, activated carbon, various test strips (e.g., cholesterol, ethanol, and glucose), pregnancy tests, urea 13The method may include a breath test using C and various stains / markers. In some embodiments, the labeling portion is a fluorescent dye or dark quencher selected from the group consisting of coumarin, cyanine dyes, azo dyes, acridine, fluorone, oxazine, phenanthridine, naphthalimide, rhodamine, benzopyrone, perylene, benzantrone, and benzoxantrone. In certain non-limiting embodiments, the fluorescent dye is a residue of a compound selected from the group consisting of coumarin, fluorescein, cyanine 3 (Cy3), cyanine 5 (Cy5), cyanine (Cy7), Alexa dye, bodipy derivatives, (E)-2-(4-(phenyldiazenyl)phenoxy)acetic acid, 3-(3',3'-dimethyl-6-nitrospiro[chromen-2,2'-indoline]-1'-yl)propanoate (spiropyran), 3,5-dihydroxybenzoate, and (E)-2-(4-(phenyldiazenyl)phenoxy)acetic acid or a combination thereof.

[0088]

[0174] As used herein, the term “radionic nuclide” encompasses any compound or chemical part containing one or more radioisotopes. A radioisotope is an element that emits radiation. Examples include α-emitting, β-emitting, or γ-emitting materials.Suitable radionuclides for use as radioactive agents include, but are not limited to, carbon-11, fluorine-18, bromine-76, or iodine-123 and iodine-124, and metallic radionuclides include antimony-124, antimony-125, arsenic-74, barium-103, barium-140, beryllium-7, bismuth-206, bismuth-207, cadmium-109, cadmium-115m, calcium-45, cerium-139, cerium-141, cerium-144, cesium-137, chromium-51, and cobalt. -55, Cobalt-56, Cobalt-57, Cobalt-58, Cobalt-60, Cobalt-64, Copper-67, Erbium-169, Europium-152, Gallium-64, Gallium-68, Gadolinium-153, Gadolinium-157, Gold-195, Gold-199, Hafnium-175, Hafnium-175~181, Holmium-166, Indium-110, Indium-111, Iridium-192, Iron-55, Iron-59, Krypton-85, Lead-210, Manganese-54, Mercury-197, Mercury-203 Molybdenum-99, Neodymium-147, Neptunium-237, Nickel-63, Niobium-95, Osmium-185+191, Palladium-103, Platinum-195m, Praseodymium-143, Promethium-147, Protactinium-233, Radium-226, Rhenium-186, Rhenium-188, Rubidium-86, Ruthenium-103, Ruthenium-106, Scandium-44, Scandium-6, Selenium-75, Silver-110m, Silver-111, Sodium-22, Strontium-85, S Contains trontium-89, strontium-90, sulfur-35, tantalum-182, technetium-99m, tellurium-125, tellurium-132, thallium-204, thorium-228, thorium-232, thallium-170, tin-113, tin-114, tin-117m, titanium-44, tungsten-185, vanadium-48, vanadium-49, ytterbium-169, yttrium-86, yttrium-88, yttrium-90, yttrium-91, zinc-65, or zirconium-95.In certain embodiments, the radionuclide is selected from, for example, 99m technetium, 201 thallium, 111 indium, 67 gallium, 90 yttrium, 177 lutetium, or 123 iodine.

[0089]

[0175] Numerous active agents are known for treating or preventing various eye conditions or complications, such as infections, inflammation (e.g., postoperative inflammation), macular edema, neovascularization, age-related macular degeneration (neovascular or atrophic), glaucoma, diabetic retinopathy, retinopathy of prematurity, uveitis, corneal transplant rejection, fibrosis (e.g., capsular fibrosis), posterior capsule opacity, retinal vein occlusion, and infections.

[0090]

[0176] The field of activators that can be incorporated into polymer materials may include anti-inflammatory agents, anti-angiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), intraocular pressure (IOP) lowering agents, anti-infective agents, antibiotics, anti-mitotic agents, antiviral agents, antifungal agents, antimetabolites, antifibrotic agents, glaucoma agents, anti-angiogenic agents, integrins, integrin antagonists, complement antagonists, cytokines, cytokine inhibitors, antibody blocking agents, angiogenesis inhibitors, vaccines, immunomodulators, anticoagulants, antineoplastic agents, anesthetics, analgesics, adrenaline agonists or antagonists, cholinergic agonists or antagonists, enzymes, enzyme inhibitors, neuroprotective agents, cytoprotective agents, regenerative agents, antisense oligonucleotides, aptamers, antibodies, or combinations thereof.

[0091]

[0177] Activators may consist of proteins, peptides, lipids, carbohydrates, hormones, metals, radioactive elements and compounds, or combinations thereof.

[0178] In some embodiments, the corticosteroid may include hydrocortisone, loteprednol, cortisol, cortisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, aldosterone, or fludrocortisone.

[0092]

[0179] In some embodiments, the NSAID may include diclofenac (e.g., diclofenac sodium), flurbiprofen (e.g., flurbiprofen sodium), ketrolac (e.g., ketrolac tromethamine), bromfenac, or nepafenac.

[0093]

[0180] In some embodiments, the IOP-reducing agent and / or glaucoma agent is a prostaglandin analog (e.g., bimatoprost, latanoprost, travoprost, or latanoprostenbunod), a rho kinase inhibitor (e.g., netaludil), an adrenaline agonist (epinephrine or dipivefrin), a beta-adrenergic antagonist also known as a beta-blocker (e.g., timolol, levobunolol, metipranolol, carteolol, or betaxolol), an alpha-2-adrenergic agonist (e.g., apraclonidine, brimonidine, or brimonidine tartrate), or a carbonic anhydrase inhibitor (e.g., brinzolamide, diclofenamide, metazolamide). It may contain acetazolamide (acetazolamide or dorzolamide), pilocarpine, ecothiophate, demercarium, physostigmine, and / or isofluorophate.

[0094]

[0181] In some embodiments, the antiinfective agent may include antibiotics comprising ciprofloxacin, tobramycin, erythromycin, ofloxacin, gentamicin, fluoroquinolone antibiotics, moxifloxacin and / or gatifloxacin; antiviral agents comprising ganciclovir, idoxuridine, vidarabine and / or trifluridine; and / or antifungal agents comprising amphotericin B, natamycin, voriconazole, fluconazole, miconazole, clotrimazole, ketoconazole, posaconazole, echinocandin, caspofungin and / or micafungin.

[0095]

[0182] In some embodiments, the antimetabolite may include methotrexate, mycophenolate, or azathioprine.

[0183] In some embodiments, the antifibrotic agent may include mitomycin C or 5-fluorouracil.

[0096]

[0184] In some embodiments, the angiogenesis inhibitor may include anti-VEGF agents (e.g., aflibercept, ranibizumab, bevacizumab), PDGF-B inhibitors (e.g., Fovista®), complement antagonists (e.g., eculizumab), tyrosine kinase inhibitors (e.g., sunitinib, axitinib), and / or integrin antagonists (e.g., natalizumab and vedolizumab).

[0097]

[0185] In some embodiments, the cytoprotective agent may include ebselen, sulforaphane, ortiplasm, or dimethyl fumarate.

[0186] In some embodiments, the neuroprotective agent may include ursodiol, memantine, or acetylcysteine.

[0098]

[0187] In some embodiments, the anesthetic agent may include lidocaine, propalacaine, or bupivacaine.

[0188] In some embodiments, the activator may be dexamethasone, ketrolac, diclofenac, vancomycin, moxifloxacin, gatifloxacin, becifloxacin, travoprost, 5-fluorouracil, methotrexate, mitomycin C, prednisolone, bevacizumab (Avastin®), ranibizumab (Lucentis®), sunitinib, pegaptanib (Macugen®), timolol, latanoprost, brimonidine, nepafenac, bromfenac, triamcinolone, difluprednate, fluocinonide, aflibercept, or a combination thereof. In some embodiments, the activator may be dexamethasone, ketrolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the activator is dexamethasone. In some embodiments, the activator is ketrolac. In some embodiments, the active ingredient is dexamethasone.

[0099]

[0189] In some embodiments, ophthalmic articles may include inertants (e.g., polymers). The function of the inert component may be to impart certain physical properties to the ophthalmic article, such as bulk, adhesion, hardness, flexibility, fit, erosion resistance, color, and opacity, as well as to influence the release rate of the inertant (e.g., inert component). Various inert components may be used in ophthalmic articles and also in approved activators (e.g., drug products) and may be biocompatible. In some embodiments, ophthalmic articles may also include pigments to assist in the surgeon's visualization.

[0100]

[0190] In some embodiments, ophthalmic articles may also include one or more excipients and / or disintegrants. Excipients may include preservatives, permeability enhancers, plasticizers, lubricants, emulsifiers, solubilizers, suspending agents, stiffeners, thickeners, buffers, acidifiers, alkalizing agents, thickeners, colorants, release modifiers, controlled release agents, opacifiers, stabilizers, gelling agents, antioxidants, dispersants, hydroxypropylcellulose, sodium carboxymethylcellulose, croscarmellose sodium, hyaluronic acid, and / or albumin. Excipients may include one or more described, for example, by Raymond C. Rowe et al., Handbook of Pharmaceutical Excipients (6th edition, 2009), which are incorporated herein by reference in their entirety.

[0101]

[0191] Disintegrants can be superdisintegrants. Non-limiting examples of suitable disintegrants may include cross-linked cellulose (e.g., croscarmellose, Ac-Di-Sol, Nymce ZSX, Primellose, SoluTab, VIVASOL), microcrystalline cellulose, alginates, cross-linked PVP (e.g., crospovidone, Kollidon, Polyplasdone), cross-linked starch, soybean polysaccharides, calcium silicate, and salts thereof.

[0102]

[0192] For example, excipients and / or disintegrants may be present in 3% to 25% by weight of the ophthalmic article, and in some cases, 3% to 20% by weight. Disintegrants may be useful at over 25% by weight for delivery times of less than about one week, while less than 3% may be useful for extended delivery times of more than 6 to 9 months.

[0103]

[0193] In some embodiments, the ophthalmic article may contain at least or about 0.1% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 0.5% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 1.0% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 10% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 15% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 20% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain 25% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 30% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 35% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 45% to 50% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 40% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 35% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 30% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 25% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 20% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 15% by weight of excipients and / or disintegrants. In some embodiments, the ophthalmic article may contain about 5% to 10% by weight of excipients and / or disintegrants.

[0104]

[0194] In some embodiments, ophthalmic articles may be formed by mixing, for example, a polymer material with a loaded amount of activator and / or diagnostic agent to form a matrix dispersion or solution. In some embodiments, ophthalmic articles may be formed using a biodegradable matrix and / or non-biodegradable material.

[0105]

[0195] In some embodiments, the non-biodegradable material may include methacrylate, acrylate and / or copolymers thereof, silicone, and / or polymers and / or copolymers of vinyl acetate, vinylpyrrolidone and / or vinyl alcohol. Methacrylate may include poly(methyl acrylate) (PMA) or poly(methyl methacrylate) (PMMA). Vinyl acetate may include vinyl acetate or ethylene vinyl acetate (EVA).

[0106]

[0196] Activators and / or diagnostic agents can be homogeneously dispersed as a solid, or uniformly or partially dissolved, as long as uniformity and homogeneity are maintained. Therefore, in some examples, activators and / or diagnostic agents can be homogeneously combined with a polymer matrix such that at least a portion (e.g., the whole) of the ophthalmic article is homogeneous or substantially homogeneous. For example, homogeneity can extend throughout the ophthalmic article, resulting in the ophthalmic article essentially consisting of a homogeneously mixed matrix, as well as activators and / or diagnostic agents and additives as needed. The loading volume can be selected to correspond to a desired dosage during diffusion. In some cases, the loading volume can take into account the polymer material, as well as diffusion characteristics such as the activator and / or diagnostic agent, residual activators and / or diagnostic agents, and delivery time. The matrix dispersion can then be formed into a device shape using any preferred technique. For example, the matrix dispersion can be cast, sprayed and dried, extruded, punched, etc.

[0107]

[0197] In some embodiments, ophthalmic articles (e.g., biocompatible and / or biodegradable matrices) can be configured to biodegrade or bio-erode to achieve the release (e.g., controlled release) of activators (e.g., therapeutic agents) and / or diagnostic agents from a material (e.g., polymer material). In some embodiments, ophthalmic articles (e.g., biocompatible and / or biodegradable matrices) can be configured to biodegrade or bio-erode over a period of several days, weeks, or months to achieve the release of an effective amount (e.g., a therapeutically effective amount) of activators (e.g., therapeutic agents) and / or diagnostic agents from a polymer material (e.g., polymer matrix).

[0108]

[0198] In some embodiments, ophthalmic articles for delivering activators (e.g., drug delivery agents) and / or diagnostic agents to the eye may contain bioerosive polymers, which may be either natural or synthetic polymers that spontaneously degrade when placed in a biological environment. Mechanisms of bioerosion include ester hydrolysis, enzymatic degradation, or reduction of disulfide bonds. Examples of bioerosive polymers may include polylactides, polyglycolides, polycaprolactones, poly(trimethylene carbonate), chitosan, polyethylene glycol, poly-beta-aminoesters, poly-L-malic acid, hyaluronic acid, peptides, nucleic acids, or dextran polymers.

[0109]

[0199] In some embodiments, articles for drug delivery to the eye may be designed to release the drug over a short period of time (e.g., the first 24–48 hours after surgery). “Burst release” may be desirable to prevent immediate postoperative infection or inflammation. In other embodiments, articles for drug delivery to the eye may be designed to release the drug over a long period of time (e.g., several days to several weeks or even several months after surgery). Such sustained release may be desirable to treat more chronic conditions such as glaucoma, posterior capsule opacity, or macular edema. In some embodiments, the ophthalmic articles described herein may be targeted for relatively short delivery durations, e.g., less than 8 weeks. In some examples, the activators and / or diagnostic agents have delivery durations of about 1 week to about 6 or 8 weeks. In some examples, the activators and / or diagnostic agents have delivery durations of about 2 weeks to about 6 or 8 weeks. In some examples, the activators and / or diagnostic agents have delivery durations of about 3 weeks to about 6 or 8 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 4 weeks to approximately 6 or 8 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 2 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 3 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 4 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 5 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 6 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 7 weeks. In some cases, the activator and / or diagnostic agent has a delivery duration of approximately 1 week to approximately 8 weeks.

[0110]

[0200] In some embodiments, the material (e.g., a biocompatible matrix), as well as the activator (e.g., a drug) and / or diagnostic agent, may be selected to achieve release for more than 7 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for at least about 7 days. In some embodiments, the activator and / or diagnostic agent is released from the biocompatible material (e.g., a biocompatible polymer matrix) for about 5–30 days, 5–21 days, 5–14 days, 5–10 days, 7–30 days, 7–21 days, 7–14 days, or 7–10 days.

[0111]

[0201] In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 day to about 36 months. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of at least about 34 months, at least about 32 months, at least about 30 months, at least about 28 months, at least about 26 months, at least about 24 months, at least about 22 months, at least about 20 months, at least about 18 months, at least about 16 months, at least about 14 months, at least about 12 months, at least about 10 months, at least about 8 months, at least about 6 months, at least about 4 months, at least about 2 months, at least about 1 month, at least about 3 weeks, at least about 2 weeks, at least about 1 week, at least about 6 days, at least about 5 days, at least about 4 days, at least about 3 days, at least about 2 days, or at least about 1 day. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for at least about 7 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for at least about 14 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for at least about 45 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for at least about 90 days.

[0112]

[0202] In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 day to about 36 months. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of up to about 34 months, up to about 32 months, up to about 30 months, up to about 28 months, up to about 26 months, up to about 24 months, up to about 22 months, up to about 20 months, up to about 18 months, up to about 16 months, up to about 14 months, up to about 12 months, up to about 10 months, up to about 8 months, up to about 6 months, up to about 4 months, up to about 2 months, up to about 1 month, up to about 3 weeks, up to about 2 weeks, up to about 1 week, up to about 6 days, up to about 5 days, up to about 4 days, up to about 3 days, up to about 2 days, or up to about 1 day. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for up to about 7 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for up to about 14 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for up to about 45 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) for up to about 90 days.

[0113]

[0203] In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 week to about 36 months, about 1 week to about 34 months, about 1 week to about 32 months, about 1 week to about 30 months, about 1 week to about 30 months, about 1 week to about 28 months, about 1 week to about 26 months, about 1 week to about 24 months, about 1 week to about 22 months, about 1 week to about 20 months, about 1 week to about 18 months, about 1 week to about 16 months, about 1 week to about 14 months, about 1 week to about 12 months, about 1 week to about 10 months, about 1 week to about 8 months, about 1 week to about 6 months, about 1 week to about 4 months, about 1 week to about 2 months, about 1 week to about 1 month, about 1 week to about 3 weeks, or about 1 week to about 2 weeks. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 to 7 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 to 14 days. In some embodiments, the activator and / or diagnostic agent may be released from the biocompatible polymer matrix (e.g., a biocompatible copolymer matrix) over a period of about 1 to 45 days.

[0114]

[0204] In some examples, a therapeutically effective dose may be released over a period ranging from approximately 1 day to approximately 10 weeks. In other examples, a therapeutically effective dose may be released over a period ranging from approximately 1 day to approximately 3 weeks, approximately 2 weeks to approximately 6 weeks, or approximately 5 weeks to approximately 8 weeks. In some embodiments, a therapeutically effective dose may be released over a period of at least approximately 1 day to approximately 36 months.

[0115]

[0205] In some embodiments, a therapeutically effective dose may be released over at least about 34 months, at least about 32 months, at least about 30 months, at least about 28 months, at least about 26 months, at least about 24 months, at least about 22 months, at least about 20 months, at least about 18 months, at least about 16 months, at least about 14 months, at least about 12 months, at least about 10 months, at least about 8 months, at least about 6 months, at least about 4 months, at least about 2 months, at least about 1 month, at least about 3 weeks, at least about 2 weeks, at least about 1 week, at least about 6 days, at least about 5 days, at least about 4 days, at least about 3 days, at least about 2 days, or at least about 1 day. In some embodiments, a therapeutically effective dose may be released over at least about 7 days. In some embodiments, a therapeutically effective dose may be released over at least about 14 days. In some embodiments, a therapeutically effective dose may be released over at least about 45 days. In some embodiments, a therapeutically effective dose may be released over at least about 90 days.

[0116]

[0206] In some embodiments, the therapeutically effective dose may be released over a maximum of approximately 34 months, 32 months, 30 months, 28 months, 26 months, 24 months, 22 months, 20 months, 18 months, 16 months, 14 months, 12 months, 10 months, 8 months, 6 months, 4 months, 2 months, 1 month, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day. In some embodiments, the therapeutically effective dose may be released over a maximum of approximately 7 days. In some embodiments, the therapeutically effective dose may be released over a maximum of approximately 14 days. In some embodiments, the therapeutically effective dose may be released over a maximum of approximately 45 days. In some embodiments, a therapeutically effective dose may be released over a period of up to approximately 90 days.

[0117]

[0207] In some embodiments, a therapeutically effective dose may be released over a period of approximately 1 week to 36 months, 1 week to 34 months, 1 week to 32 months, 1 week to 30 months, 1 week to 30 months, 1 week to 28 months, 1 week to 26 months, 1 week to 24 months, 1 week to 22 months, 1 week to 20 months, 1 week to 18 months, 1 week to 16 months, 1 week to 14 months, 1 week to 12 months, 1 week to 10 months, 1 week to 8 months, 1 week to 6 months, 1 week to 4 months, 1 week to 2 months, 1 week to 1 month, 1 week to 3 weeks, or 1 week to 2 weeks. In some embodiments, a therapeutically effective dose may be released over a period of approximately 1 day to 7 days. In some embodiments, a therapeutically effective dose may be released over a period of approximately 1 day to 14 days. In some embodiments, the therapeutically effective dose may be released over a period of approximately 1 to 45 days. In some embodiments, the therapeutically effective dose may be released over a period of approximately 1 to 90 days.

[0118]

[0208] The effective dose (e.g., therapeutic dose) may range from about 1 microgram (μg) to about 10 milligrams (mg). The effective dose may depend on the activator and / or diagnostic agent used, as well as the severity of the condition or complication. In some embodiments, the effective dose may range from about 50 μg to about 800 μg. In some embodiments, the effective amount or effective dose is approximately 50 μg to 100 μg, approximately 50 μg to 150 μg, approximately 50 μg to 200 μg, approximately 50 μg to 250 μg, approximately 50 μg to 300 μg, approximately 50 μg to 350 μg, approximately 50 μg to 400 μg, approximately 50 μg to 450 μg, approximately 50 μg to 500 μg, approximately 50 μg to 550 μg, approximately 50 μg to 600 μg, approximately 50 μg to 650 μg, approximately 50 μg to 700 μg, approximately 50 μg to 750 μg, and approximately 50 μg. g ~ approx. 800 μg, approx. 100 μg ~ approx. 150 μg, approx. 100 μg ~ approx. 200 μg, approx. 100 μg ~ approx. 250 μg, approx. μg, approx. 100 μg to approx. 500 μg, approx. 100 μg to approx. 550 μg, approx. 100 μg to approx. 600 μg, approx. 100 μg to approx. 650 μg, approx. 0μg to about 200μg, about 150μg to about 250μg, about 150μg to about 300μg, about 150μg to about 350μg, about 150μg to about 400μg, about 150μg to about 450μg, about 150μg to about 500μg, about 150μg to about 5 50μg, about 150μg to about 600μg, about 150μg to about 650μg, about 150μg to about 700μg, about 150μg to about 750μg, about 150μg to about 800μg, about 200μg to about 250μg, about 200μg to about 300μg, about 200μg~about 350μg, about 200μg~about 400μg, about 200μg~about 450μg, about 200μg~about 500μg, about 200μg~about 550μg, about 200μg~about 600μg, about 200μg~about 650μg, about 200μg~ Approximately 700μg, approximately 200μg to approximately 750μg, approximately 200μg to approximately 800μg, approximately 250μg to approximately 300μg, approximately 250μg to approximately 350μg, approximately 250μg to approximately 400μg, approximately 250μg to approximately 450μg, approximately 250μg to approximately 500μg,Approximately 250μg to approximately 550μg, approximately 250μg to approximately 600μg, approximately 250μg to approximately 650μg, approximately 250μg to approximately 700μg, approximately 250μg to approximately 750μg, approximately 250μg to approximately 800μg, approximately 300μg to approximately 350μg, approximately 300μg ~about 400μg, about 300μg to about 450μg, about 300μg to about 500μg, about 300μg to about 550μg, about 300μg to about 600μg, about 300μg to about 650μg, about 300μg to about 700μg, about 300μg to about 750μg , about 300μg to about 800μg, about 350μg to about 400μg, about 350μg to about 450μg, about 350μg to about 500μg, about 350μg to about 550μg, about 350μg to about 600μg, about 350μg to about 650μg, about 350μg g ~ approx. 700 μg, approx. 350 μg ~ approx. 750 μg, approx. 350 μg ~ approx. 800 μg, approx. 400 μg ~ approx. 450 μg, approx. 400 μg ~ approx. g, about 400μg to about 700μg, about 400μg to about 750μg, about 400μg to about 800μg, about 450μg to about 500μg, about 450μg to about 550μg, about 450μg to about 600μg, about 450μg to about 650μg, about 450 μg ~ approx. 700 μg, approx. 450 μg ~ approx. 750 μg, approx. 500 μg ~ approx. 550 μg, approx. 500 μg ~ approx. 600 μg, approx. The effective amount or effective dose may be in the range of approximately 50 μg to 600 μg, approximately 550 μg to 650 μg, approximately 550 μg to 700 μg, approximately 550 μg to 750 μg, approximately 550 μg to 800 μg, approximately 600 μg to 650 μg, approximately 600 μg to 700 μg, approximately 600 μg to 750 μg, approximately 650 μg to 700 μg, approximately 650 μg to 750 μg, approximately 600 μg to 800 μg, approximately 700 μg to 750 μg, or approximately 750 μg to 800 μg. In some embodiments, the effective amount or effective dose may be in the range of approximately 50 μg to 200 μg. In some embodiments, the effective amount or effective dose may be in the range of about 50 μg to about 400 μg. In some embodiments, the effective amount or effective dose may be in the range of about 50 μg to about 700 μg.

[0119]

[0209] In some embodiments, the effective amount or effective dose may be at least about 50 μg, at least about 60 μg, at least about 70 μg, at least about 80 μg, at least about 90 μg, at least about 100 μg, at least about 150 μg, at least about 200 μg, at least about 250 μg, at least about 300 μg, at least about 350 μg, at least about 400 μg, at least about 450 μg, at least about 500 μg, at least about 600 μg, at least about 650 μg, at least about 700 μg, at least about 750 μg, at least about 800 μg, at least about 850 μg, at least about 900 μg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 6 mg, at least about 7 mg, at least about 8 mg, at least about 9 mg, or at least about 10 mg. In some embodiments, the effective amount or effective dose may be at least about 150 μg. In some embodiments, the effective amount or effective dose may be at least about 300 μg. In some embodiments, the effective amount or effective dose may be at least about 600 μg.

[0120]

[0210] In some embodiments, the effective amount or effective dose is at most about 50 μg, at most about 60 μg, at most about 70 μg, at most about 80 μg, at most about 90 μg, at most about 100 μg, at most about 150 μg, at most about 200 μg, at most about 250 μg, at most about 300 μg, at most about 350 μg, at most about 400 μg, at most about 450 μg, at most about 500 μg, and at most However, it could be approximately 600 μg, at most approximately 650 μg, at most approximately 700 μg, at most approximately 750 μg, at most approximately 800 μg, at most approximately 850 μg, at most approximately 900 μg, at most approximately 1 mg, at most approximately 2 mg, at most approximately 3 mg, at most approximately 4 mg, at most approximately 5 mg, at most approximately 6 mg, at most approximately 7 mg, at most approximately 8 mg, at most approximately 9 mg, or at most approximately 10 mg. In some embodiments, the effective amount or effective dose may be at most approximately 150 μg. In some embodiments, the effective amount or effective dose may be at most approximately 300 μg. In some embodiments, the effective amount or effective dose may be at most approximately 600 μg.

[0121]

[0211] In some embodiments, the effective amount or effective dose may be about 50 μg, about 60 μg, about 70 μg, about 80 μg, about 90 μg, about 100 μg, about 150 μg, about 200 μg, about 250 μg, about 300 μg, about 350 μg, about 400 μg, about 450 μg, about 500 μg, about 600 μg, about 650 μg, about 700 μg, about 750 μg, about 800 μg, about 850 μg, about 900 μg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, or about 10 mg. In some embodiments, the effective amount or effective dose may be about 150 μg. In some embodiments, the effective amount or effective dose may be about 300 μg. In some embodiments, the effective amount or effective dose may be about 600 μg.

[0122]

[0212] In some cases, ophthalmic articles may release approximately 1 μg to 10 mg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 36 months. In some additional cases, ophthalmic articles may release approximately 1 μg to 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 12 weeks.

[0123]

[0213] In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 6 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 8 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 10 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 12 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 14 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 16 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 18 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 20 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 22 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 24 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 26 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 28 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 30 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 32 months.In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 34 months. In some additional examples, ophthalmic articles may release approximately 1 μg to approximately 500 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 36 months.

[0124]

[0214] In yet another example, an ophthalmic article may release approximately 100 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 2 to 8 weeks. In yet another example, an ophthalmic article may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg, of activators and / or diagnostic agents over a period of approximately 2 to 8 weeks. In yet another example, an ophthalmic article may release approximately 1 μg to 300 μg over 2 to 3 weeks. In yet another example, an ophthalmic article may release 100 μg to 600 μg over 6 to 8 weeks.

[0125]

[0215] In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 6 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 8 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 10 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 12 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 14 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 16 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 18 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 20 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 22 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg, of activators and / or diagnostic agents over a period of approximately 1 week to approximately 24 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg, of activators and / or diagnostic agents over a period of approximately 1 week to approximately 26 months.In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 28 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 30 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg of activators and / or diagnostic agents over a period of approximately 1 week to approximately 32 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg, of activators and / or diagnostic agents over a period of approximately 1 week to approximately 34 months. In some additional examples, ophthalmic articles may release approximately 100 μg to 500 μg, or approximately 200 μg to 1000 μg, of activators and / or diagnostic agents over a period of approximately 1 week to approximately 36 months.

[0126]

[0216] In some cases, ophthalmic articles may deliver an average of approximately 0.1 μg to approximately 1 μg of activators and / or diagnostic agents per day during the release period. In other cases, ophthalmic articles may deliver an average of approximately 1 μg to approximately 10 μg of activators and / or diagnostic agents per day during the release period. In yet another case, ophthalmic articles may deliver an average of approximately 10 μg to approximately 50 μg of activators and / or diagnostic agents per day during the release period.

[0127]

[0217] In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 100 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 150 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 200 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 250 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 300 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 350 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 400 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 450 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 500 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 550 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 600 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 650 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 700 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 750 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to approximately 800 μg of activators and / or diagnostic agents per day during its release period.In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 850 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 900 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg to 950 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 1 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 5 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 10 μg of activators and / or diagnostic agents per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 50 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 100 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 200 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 300 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 400 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 500 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 600 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 700 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 800 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 900 μg of activating agent and / or diagnostic agent per day during its release period. In yet another example, an ophthalmic article may deliver an average of approximately 1,000 μg of activating agent and / or diagnostic agent per day during its release period.

[0128]

[0218] In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of about 5% by weight (wt) to about 50% by weight. In some embodiments, the activator and / or diagnostic agent may be present at concentrations of about 5% to about 10% by weight, about 5% to about 15% by weight, about 5% to about 20% by weight, about 5% to about 25% by weight, about 5% to about 30% by weight, about 5% to about 35% by weight, about 5% to about 40% by weight, about 5% to about 45% by weight, about 10% to about 15% by weight, about 10% to about 20% by weight, and about 10% by weight % to about 25% by weight, about 10% to about 30% by weight, about 10% to about 35% by weight, about 10% to about 40% by weight, about 10% to about 45% by weight, about 10% to about 50% by weight, about 1 5% to about 20% by weight, about 15% to about 25% by weight, about 15% to about 30% by weight, about 15% to about 35% by weight, about 15% to about 40% by weight, about 15% to about 45% by weight, About 15% to about 50% by weight, about 20% to about 25% by weight, about 20% to about 30% by weight, about 20% to about 35% by weight, about 20% to about 40% by weight, about 20% to about 45% by weight Amount%, about 20% to about 50% by weight, about 25% to about 30% by weight, about 25% to about 35% by weight, about 25% to about 40% by weight, about 25% to about 45% by weight, about 25% to about 5 The activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of 0% by weight, approximately 30% to approximately 35% by weight, approximately 30% to approximately 40% by weight, approximately 30% to approximately 45% by weight, approximately 30% to approximately 50% by weight, approximately 35% to approximately 40% by weight, approximately 35% to approximately 45% by weight, approximately 35% to approximately 50% by weight, approximately 40% to approximately 45% by weight, approximately 40% to approximately 50% by weight, or approximately 45% to approximately 50% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of approximately 5% to approximately 25% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of approximately 5% to approximately 15% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of at least approximately 5% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of at least about 10% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of at least about 20% by weight.

[0129]

[0219] In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, at least about 20% by weight, at least about 25% by weight, at least about 30% by weight, at least about 35% by weight, at least about 40% by weight, at least about 45% by weight, or at least about 50% by weight.

[0130]

[0220] In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of up to about 5% by weight, up to about 10% by weight, up to about 15% by weight, up to about 20% by weight, up to about 25% by weight, up to about 30% by weight, up to about 35% by weight, up to about 40% by weight, up to about 45% by weight, or up to about 50% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of up to about 5% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of up to about 10% by weight. In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at a concentration of up to about 20% by weight.

[0131]

[0221] In some embodiments, the activator and / or diagnostic agent may be present in the ophthalmic article at concentrations of about 5% by weight, about 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, or about 50% by weight.

[0132]

[0222] In some embodiments, the molecular weight, molecular mass, or molecular size of the activator and / or diagnostic agent may affect the delivery of the activator and / or diagnostic agent to the eye (e.g., the posterior segment). Therefore, in some examples, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 250,000 Datons (Da) or less. In further examples, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 200,000 Da or less. In even further examples, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 190,000 Da or less. In even further examples, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 180,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 170,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 160,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 150,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 140,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 130,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 120,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 110,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 100,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 90,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 80,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 70,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 60,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 50,000 Da or less.In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 40,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 30,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 20,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 10,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 5,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 1,000 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 500 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 400 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 300 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 200 Da or less. In yet another example, the activator and / or diagnostic agent may have a molecular weight or molecular mass of 100 Da or less.

[0133]

[0223] In some embodiments, one, two, or more ophthalmic articles can be introduced or implanted in one eye to achieve an effective dose (e.g., a therapeutically effective dose) and / or an effective size (e.g., a therapeutically effective dose). In some embodiments, at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more, ophthalmic articles can be introduced or implanted in one eye. In some embodiments, a maximum of about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ophthalmic article can be introduced or implanted in one eye. In some embodiments, at least about 1 ophthalmic article can be introduced or implanted in one eye. In some embodiments, at least about 2 ophthalmic articles can be introduced or implanted in one eye. In some embodiments, at least about 3 ophthalmic articles can be introduced or implanted in one eye. In some embodiments, at least about 4 ophthalmic articles can be introduced or implanted in one eye. In some embodiments, at least about five ophthalmic articles can be introduced or implanted per eye.

[0134]

[0224] In some embodiments, up to approximately one ophthalmic device can be introduced or implanted per eye. In some embodiments, up to approximately two ophthalmic devices can be introduced or implanted per eye. In some embodiments, up to approximately three ophthalmic devices can be introduced or implanted per eye. In some embodiments, up to approximately four ophthalmic devices can be introduced or implanted per eye. In some embodiments, up to approximately five ophthalmic devices can be introduced or implanted per eye.

[0135]

[0225] In some embodiments, approximately one ophthalmic article can be introduced or implanted per eye. In some embodiments, approximately two ophthalmic articles can be introduced or implanted per eye. In some embodiments, approximately three ophthalmic articles can be introduced or implanted per eye. In some embodiments, approximately four ophthalmic articles can be introduced or implanted per eye. In some embodiments, approximately five ophthalmic articles can be introduced or implanted per eye.

[0136]

[0226] In any of the various embodiments, one or more ophthalmic articles described herein are designed to be sized and / or shaped to bring the ophthalmic article as close as possible to the target eye. The shape and / or size of the ophthalmic article (e.g., an activator and / or diagnostic homogeneous delivery device) for delivering or administering activators and / or diagnostics to the eye can be important in terms of the amount and rate of delivery of the activator and / or diagnostics. For example, the shape and / or size of the ophthalmic article (e.g., an activator and / or diagnostic homogeneous delivery device) can be designed to ensure fast and / or slow release rates of the activator and / or diagnostics released by the ophthalmic article (e.g., an activator and / or diagnostic homogeneous delivery device), as well as large or small amounts of them, while maintaining compositional parameters suitable for a desired release profile.

[0137]

[0227] In some embodiments, the shape of the ophthalmic article may be a prism having an internal opening structure (e.g., a hole in the center). In some embodiments, the prism may be an extruded prism. The prism may be a circular prism, rectangular prism, square prism, quadrilateral prism, pentagonal prism, hexagonal prism, heptagonal prism, octagonal prism, nonagonal prism, decagonal prism, eleven-sided prism, dodecagonal prism, or a prism of another shape. In some embodiments, the prism may be a polyhedron. In some embodiments, the ophthalmic article may be an annulus, extruded annulus, torus, extruded square, extruded quadrilateral, extruded rectangle, extruded pentagon, extruded hexagon, extruded heptagon, extruded octagon, extruded nonagon, extruded decagon, extruded eleven-sided, extruded dodecagon, or extruded polygon having an internal opening structure (e.g., a hole in the center). In some embodiments, the polygon may have 3, 4, 5, 6, 7, 8, 9, or 10 sides.

[0138]

[0228] In some embodiments, the shape of the ophthalmic article may be a disc, a cylinder, a claw-shaped plug, a rod, a plate, a hemisphere, a frustum of a bent axis, a polymer wire wound around an ophthalmic device portion, and a polymer sheet enclosing an ophthalmic device portion.

[0139]

[0229] In some embodiments, the ophthalmic article may include an internal structure for coupling with an ophthalmic device portion. The internal structure may be a hole. For example, any ophthalmic article of any of the shapes disclosed herein may include a hole at its center for coupling with an intraocular lens. In some embodiments, the shape of the ophthalmic article and / or internal structure may be identical to the shape of the ophthalmic device (e.g., intraocular device) portion to which the ophthalmic article is coupled. For example, the shape of the ophthalmic article and / or internal structure may be identical to the shape of the haptics of the intraocular lens. In some embodiments, the shape of the ophthalmic article and / or internal structure may differ from the shape of the ophthalmic device (e.g., intraocular device) portion to which the ophthalmic article is coupled. For example, the shape of the ophthalmic article and / or internal structure may differ from the shape of the haptics of the intraocular lens.

[0140]

[0230] In some embodiments, the shape of an ophthalmic article can be manipulated to prevent obstruction of the line of sight. For example, in some cases, the ophthalmic article may have a crescent shape, an elliptical shape (e.g., disc shape, football shape, egg shape), a rod shape, etc., in order to enlarge its size along one axis relative to the vertical axis to avoid obstructing the line of sight.

[0141]

[0231] In some embodiments, when a polymer material (e.g., a biodegradable polymer matrix) is used in an ophthalmic article (e.g., a homogeneous delivery device for activators and / or diagnostic agents), the polymer material (e.g., a biodegradable polymer matrix) can deliver varying amounts of activators and / or diagnostic agents while maintaining a desirable biodegradation profile. The amount of activators and / or diagnostic agents that the biodegradable matrix can release (e.g., release in a controllable manner) is within a specific biodegradation profile, which may depend on the composition of both the polymer matrix and one or more activators and / or diagnostic agents.

[0142]

[0232] In some embodiments, small or large amounts of activators and / or diagnostic agents may be required to deliver an effective dose (e.g., a therapeutically effective dose) to a target in order to treat or diagnose a particular condition. The overall size of the ophthalmic article may be enlarged to accommodate a large amount of activators and / or diagnostic agents. Conversely, as in another example, the size of the ophthalmic article may be reduced when a small amount of activators and / or diagnostic agents is required.

[0143]

[0233] In some embodiments, an ophthalmic article may include internal structures (e.g., pores) for bonding (e.g., attaching) around an ophthalmic device (e.g., an intraocular device) portion. For example, an ophthalmic article may include pores for bonding around the geometric shape of haptics of an intraocular lens. The pores may be circular, and the haptics may be circular or rectangular.

[0144]

[0234] In some embodiments, the dimensions or parameters of the internal structure (e.g., holes) may be less than, equal to, or greater than the corresponding dimensions or parameters of the portion of the ophthalmic device (e.g., intraocular device) to which the ophthalmic article is attached. In some embodiments, the perimeter of the internal structure (e.g., holes) of the ophthalmic article may be less than or equal to the perimeter of the portion of the ophthalmic device (e.g., intraocular device) to which the ophthalmic article is attached. In some cases, the perimeter of the holes in the ophthalmic article may be less than or equal to the perimeter of the haptics on the intraocular lens to which the ophthalmic article is attached. For example, if the cross-sectional dimensions of the haptics of an IOL (e.g., Aurovue) are approximately 1.00 mm wide × 0.32 mm, the perimeter of the holes in the ophthalmic article may be less than or equal to 2.64 mm. In some embodiments, the perimeter of the holes in the ophthalmic article may be approximately 1.57 mm. In another example, the haptic cross-sectional dimensions of an IOL (e.g., Johnson & Johnson Surgical Vision Foldable Acrylic IOL Tecnis 1 Piece) could be a rectangle approximately 0.72 × 0.46 mm wide, and the perimeter of the hole in the ophthalmic article could be less than or equal to 2.36 mm.

[0145]

[0235] In some embodiments, the perimeter of the hole in the ophthalmic article may be approximately 0.5 mm to approximately 6 mm. In some embodiments, the perimeter of the hole in the ophthalmic article may be approximately 0.5 mm to approximately 1 mm, approximately 0.5 mm to approximately 1.5 mm, approximately 0.5 mm to approximately 2 mm, approximately 0.5 mm to approximately 2.5 mm, approximately 0.5 mm to approximately 3 mm, approximately 0.5 mm to approximately 3.5 mm, approximately 0.5 mm to approximately 4 mm, approximately 0.5 mm to approximately 4.5 mm, approximately 0.5 mm to approximately 5 mm, approximately 0.5 mm to approximately 5.5 mm, approximately 0.5 mm to approximately 6 mm, approximately 1 mm to approximately 1.5 mm, approximately 1 mm to approximately 2 mm, approximately 1 mm to approximately 2.5 mm, approximately 1 mm to approximately 3 mm, about 1mm to about 3.5mm, about 1mm to about 4mm, about 1mm to about 4.5mm, about 1mm to about 5mm, about 1mm to about 5.5mm, about 1mm to about 6mm, about 1.5mm to about 2mm, about 1.5mm to about 2.5mm, about 1.5mm to about 3mm, about 1.5mm to about 3.5mm, about 1.5mm to about 4mm, about 1.5mm to about 4.5mm, about 1.5mm to about 5mm, about 1.5mm to about 5.5mm, about 1.5mm to about 6mm, about 2mm to about 2.5mm, about 2mm to about 3mm , about 2mm to about 3.5mm, about 2mm to about 4mm, about 2mm to about 4.5mm, about 2mm to about 5mm, about 2mm to about 5.5mm, about 2mm to about 6mm, about 2.5mm to about 3mm, about 2.5mm to about 3.5mm, about 2.5mm to about 4m m, about 2.5mm to about 4.5mm, about 2.5mm to about 5mm, about 2.5mm to about 5.5mm, about 2.5mm to about 6mm, about 3mm to about 3.5mm, about 3mm to about 4mm, about 3mm to about 4.5mm, about 3mm to about 5mm, about 3mm to It may be approximately 5.5mm, approximately 3mm to approximately 6mm, approximately 3.5mm to approximately 4mm, approximately 3.5mm to approximately 4.5mm, approximately 3.5mm to approximately 5mm, approximately 3.5mm to approximately 5.5mm, approximately 3.5mm to approximately 6mm, approximately 4mm to approximately 4.5mm, approximately 4mm to approximately 5mm, approximately 4mm to approximately 5.5mm, approximately 4mm to approximately 6mm, approximately 4.5mm to approximately 5mm, approximately 4.5mm to approximately 5.5mm, approximately 4.5mm to approximately 6mm, approximately 5mm to approximately 5.5mm, approximately 5mm to approximately 6mm, or approximately 5.5mm to approximately 6mm.

[0146]

[0236] In some embodiments, the perimeter of the hole in the ophthalmic article is at least about 0.5 mm, at least about 1 mm, at least about 1.2 mm, at least about 1.3 mm, at least about 1.4 mm, at least about 1.5 mm, at least about 1.6 mm, at least about 1.7 mm, at least about 1.8 mm, at least about 1.9 mm, at least about 2 mm, at least about 2.1 mm, at least about 2.2 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2. It may be 9mm, at least about 3mm, at least about 3.2mm, at least about 3.4mm, at least about 3.6mm, at least about 3.8mm, at least about 4mm, at least about 4.2mm, at least about 4.4mm, at least about 4.6mm, at least about 4.8mm, at least about 5mm, at least about 5.2mm, at least about 5.4mm, at least about 5.6mm, at least about 5.8mm, at least about 6mm, at least about 6.2mm, at least about 6.4mm, at least about 6.6mm, at least about 6.8mm, or at least about 7mm.

[0147]

[0237] In some embodiments, the perimeter of the hole in the ophthalmic article is at most about 0.5 mm, at most about 1 mm, at most about 1.2 mm, at most about 1.3 mm, at most about 1.4 mm, at most about 1.5 mm, at most about 1.6 mm, at most about 1.7 mm, at most about 1.8 mm, at most about 1.9 mm, at most about 2 mm, at most about 2.1 mm, at most about 2.2 mm, at most about 2.3 mm, at most about 2.4 mm, at most about 2.5 mm, at most about 2.6 mm, at most about 2.7 mm, at most about 2.8 mm, and at most about 2. 9mm, at most about 3mm, at most about 3.2mm, at most about 3.4mm, at most about 3.6mm, at most about 3.8mm, at most about 4mm, at most about 4.2mm, at most about 4.4mm, at most about 4.6mm, at most about 4.8mm, at most about 5mm, at most about 5.2mm, at most about 5.4mm, at most about 5.6mm, at most about 5.8mm, at most about 6mm, at most about 6.2mm, at most about 6.4mm, at most about 6.6mm, at most about 6.8mm, or at most about 7mm.

[0148]

[0238] In some embodiments, the maximum width of the internal structure of the ophthalmic device may be less than or equal to the maximum width of the portion of the ophthalmic device (e.g., intraocular device) to which the ophthalmic article is attached. For example, the maximum width of the internal structure of the ophthalmic device may be less than or equal to the maximum width of the haptics of the intraocular lens to which the ophthalmic article is attached. The maximum width of the haptics of a one-piece foldable acrylic IOL may be approximately 0.7 mm to 1.0 mm, and the maximum width of the haptics of a three-piece foldable IOL may be approximately 0.1 mm to 0.2 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be less than or equal to the diameter of the portion of the ophthalmic device (e.g., intraocular device) to which the ophthalmic article is attached. For example, the diameter of the internal structure of the ophthalmic device may be less than, equal to, or greater than the diameter of the haptics of the intraocular lens to which the ophthalmic article is attached.

[0149]

[0239] In some embodiments, the maximum width of any haptics of an IOL as specified herein may be about 0.01 mm to about 10 mm. In some embodiments, the maximum width of any haptics of an IOL as specified herein may be about 0.01 mm to about 0.05 mm, about 0.01 mm to about 0.1 mm, about 0.01 mm to about 0.5 mm, about 0.01 mm to about 1 mm, about 0.01 mm to about 1.5 mm, about 0.01 mm to about 2 mm, about 0.01 mm to about 3 mm, about 0.01 mm to about 4 mm, about 0.01 mm to about 5 mm, about 0.01 mm to about 10 mm, about 0. 05mm~about 0.1mm, about 0.05mm~about 0.5mm, about 0.05mm~about 1mm, about 0.05mm~about 1.5mm, about 0.05mm~about 2mm, about 0.05mm~about 3mm, about 0.05mm~about 4 mm, about 0.05mm to about 5mm, about 0.05mm to about 10mm, about 0.1mm to about 0.5mm, about 0.1mm to about 1mm, about 0.1mm to about 1.5mm, about 0.1mm to about 2mm, about 0.1mm to about 3 mm, about 0.1mm to about 4mm, about 0.1mm to about 5mm, about 0.1mm to about 10mm, about 0.5mm to about 1mm, about 0.5mm to about 1.5mm, about 0.5mm to about 2mm, about 0.5mm to about 3mm, about 0.5mm to about 4mm, about 0.5mm to about 5mm, about 0.5mm to about 10mm, about 1mm to about 1.5mm, about 1mm to about 2mm, about 1mm to about 3mm, about 1mm to about 4mm, about 1mm to about 5mm, about 1m The sizes may be approximately m to 10mm, approximately 1.5mm to 2mm, approximately 1.5mm to 3mm, approximately 1.5mm to 4mm, approximately 1.5mm to 5mm, approximately 1.5mm to 10mm, approximately 2mm to 3mm, approximately 2mm to 4mm, approximately 2mm to 5mm, approximately 2mm to 10mm, approximately 3mm to 4mm, approximately 3mm to 5mm, approximately 3mm to 10mm, approximately 4mm to 5mm, approximately 4mm to 10mm, or approximately 5mm to 10mm.

[0150]

[0240] In some embodiments, the maximum width of any haptics of an IOL as specified herein may be at least about 0.01 mm, at least about 0.05 mm, at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 1.1 mm, at least about 1.2 mm, at least about 1.3 mm, at least about 1.4 mm, at least about 1.5 mm, at least about 1.6 mm, at least about 1.7 mm, at least about 1.8 mm, at least about 1.9 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, or at least about 10 mm. In some embodiments, the maximum width of any haptics of an IOL as specified herein may be at least about 0.5 mm. In some embodiments, the maximum width of any haptic in an IOL as described herein may be at least about 0.07 mm. In some embodiments, the maximum width of any haptic in an IOL as described herein may be at least about 1 mm.

[0151]

[0241] In some embodiments, the maximum width of any haptics of the IOL as described herein may be at most about 0.01 mm, at most about 0.05 mm, at most about 0.1 mm, at most about 0.2 mm, at most about 0.3 mm, at most about 0.4 mm, at most about 0.5 mm, at most about 0.6 mm, at most about 0.7 mm, at most about 0.8 mm, at most about 0.9 mm, at most about 1 mm, at most about 1.1 mm, at most about 1.2 mm, at most about 1.3 mm, at most about 1.4 mm, at most about 1.5 mm, at most about 1.6 mm, at most about 1.7 mm, at most about 1.8 mm, at most about 1.9 mm, at most about 2 mm, at most about 3 mm, at most about 4 mm, at most about 5 mm, at most about 6 mm, at most about 7 mm, at most about 8 mm, at most about 9 mm, or at most about 10 mm. In some embodiments, the maximum width of any haptic of an IOL as specified herein may be at most about 1.5 mm. In some embodiments, the maximum width of any haptic of an IOL as specified herein may be at most about 1 mm. In some embodiments, the maximum width of any haptic of an IOL as specified herein may be at most about 0.5 mm.

[0152]

[0242] In some embodiments, the diameter of the internal structure of the ophthalmic device may be approximately 0.1 mm to 2.3 mm.In some embodiments, the diameter of the internal structure of the ophthalmic device may be from about 0.1 mm to about 0.3 mm, from about 0.1 mm to about 0.5 mm, from about 0.1 mm to about 0.7 mm, from about 0.1 mm to about 0.9 mm, from about 0.1 mm to about 1.1 mm, from about 0.1 mm to about 1.3 mm, from about 0.1 mm to about 1.5 mm, from about 0.1 mm to about 1.7 mm, from about 0.1 mm to about 1.9 mm, from about 0.1 mm to about 2.1 mm, from about 0.1 mm to about 2.3 mm, from about 0.3 mm to about 0.5 mm, from about 0.3 mm to about 0.7 mm, from about 0.3 mm to about 0.9 mm, from about 0.3 mm to about 1.1 mm, from about 0.3 mm to about 1.3 mm, from about 0.3 mm to about 1.5 mm, from about 0.3 mm to about 1.7 mm, from about 0.3 mm to about 1.9 mm, from about 0.3 mm to about 2.1 mm, from about 0.3 mm to about 2.3 mm, from about 0.5 mm to about 0.7 mm, from about 0.5 mm to about 0.9 mm, from about 0.5 mm to about 1.1 mm, from about 0.5 mm to about 1.3 mm, from about 0.5 mm to about 1.5 mm, from about 0.5 mm to about 1.7 mm, from about 0.5 mm to about 1.9 mm, from about 0.5 mm to about 2.1 mm, from about 0.5 mm to about 2.3 mm, from about 0.7 mm to about 0.9 mm, from about 0.7 mm to about 1.1 mm, from about 0.7 mm to about 1.3 mm, from about 0.7 mm to about 1.5 mm, from about 0.7 mm to about 1.7 mm, from about 0.7 mm to about 1.9 mm, from about 0.7 mm to about 2.1 mm, from about 0.7 mm to about 2.3 mm, from about 0.9 mm to about 1.1 mm, from about 0.9 mm to about 1.3 mm, from about 0.9 mm to about 1.5 mm, from about 0.9 mm to about 1.7 mm, from about 0.9 mm to about 1.9 mm, from about 0.9 mm to about 2.1 mm, from about 0.9 mm to about 2.3 mm, from about 1.1 mm to about 1.3 mm, from about 1.1 mm to about 1.5 mm, from about 1.1 mm to about 1.7 mm, from about 1.1 mm to about 1.9 mm, from about 1.1 mm to about 2.1 mm, from about 1.1 mm to about 2.3 mm, from about 1.3 mm to about 1.5 mm, from about 1.3 mm to about 1.7 mm, from about 1.3 mm to about 1.9 mm, from about 1.3 mm to about 2.1 mm, from about 1.3 mm to about 2.3 mm, from about 1.5 mm to about 1.7 mm, from about \alpha mm to about 1.9 mm, from about 1.5 mm to about 2.1 mm, from about 1.5 mm to about 2.3 mm, from about 1.7 mm to about 1.9 mm, from about 1.7 mm to about 2.1 mm, from about 1.7 mm to about 2.3 mm, from about 1.9 mm to about \alpha mm, from about \alpha mm to about 2.3 mm, or from about 2.1 mm to about 2.3 mm.In some embodiments, the diameter of the internal structure of the ophthalmic device may be approximately 0.1 mm to approximately 1 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be approximately 0.1 mm to approximately 0.7 mm.

[0153]

[0243] In some embodiments, the diameter of the internal structure of the ophthalmic device is at least about 0.1 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, and less The diameters may be approximately 1.2 mm, at least approximately 1.25 mm, at least approximately 1.3 mm, at least approximately 1.35 mm, at least approximately 1.4 mm, at least approximately 1.45 mm, at least approximately 1.5 mm, at least approximately 1.55 mm, at least approximately 1.6 mm, at least approximately 1.65 mm, at least approximately 1.7 mm, at least approximately 1.75 mm, at least approximately 1.8 mm, at least approximately 1.85 mm, at least approximately 1.9 mm, at least approximately 1.95 mm, at least approximately 2 mm, at least approximately 2.05 mm, at least approximately 2.1 mm, at least approximately 2.15 mm, at least approximately 2.2 mm, at least approximately 2.25 mm, or at least approximately 2.3 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be at least approximately 0.1 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be at least approximately 0.5 mm.

[0154]

[0244] In some embodiments, the diameter of the internal structure of the ophthalmic device is at most about 0.1 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, at most about 0.65 mm, at most about 0.7 mm, at most about 0.75 mm, at most about 0.8 mm, at most about 0.85 mm, at most about 0.9 mm, at most about 0.95 mm, at most about 1 mm, at most about 1.05 mm, at most about 1.1 mm, at most about 1.15 mm, at most However, it may be approximately 1.2 mm, at most approximately 1.25 mm, at most approximately 1.3 mm, at most approximately 1.35 mm, at most approximately 1.4 mm, at most approximately 1.45 mm, at most approximately 1.5 mm, at most approximately 1.55 mm, at most approximately 1.6 mm, at most approximately 1.65 mm, at most approximately 1.7 mm, at most approximately 1.75 mm, at most approximately 1.8 mm, at most approximately 1.85 mm, at most approximately 1.9 mm, at most approximately 1.95 mm, at most approximately 2 mm, at most approximately 2.05 mm, at most approximately 2.1 mm, at most approximately 2.15 mm, at most approximately 2.2 mm, at most approximately 2.25 mm, or at most approximately 2.3 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be at most approximately 0.5 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be at most approximately 1 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be at most about 1.5 mm.

[0155]

[0245] In some embodiments, the diameter of the internal structure of the ophthalmic device is approximately 0.1 mm, 0.2 mm, 0.25 mm, 0.3 mm, 0.35 mm, 0.4 mm, 0.45 mm, 0.5 mm, 0.55 mm, 0.6 mm, 0.65 mm, 0.7 mm, 0.75 mm, 0.8 mm, 0.85 mm, 0.9 mm, 0.95 mm, 1 mm, 1.05 mm, 1.1 mm, and 1.15 mm. The diameter may be approximately 1.2 mm, 1.25 mm, 1.3 mm, 1.35 mm, 1.4 mm, 1.45 mm, 1.5 mm, 1.55 mm, 1.6 mm, 1.65 mm, 1.7 mm, 1.75 mm, 1.8 mm, 1.85 mm, 1.9 mm, 1.95 mm, 2 mm, 2.05 mm, 2.1 mm, 2.15 mm, 2.2 mm, 2.25 mm, or 2.3 mm. In some embodiments, the diameter of the internal structure of the ophthalmic device may be approximately 0.5 mm.

[0156]

[0246] Figures 1A and 1B schematically illustrate examples of ophthalmic articles (e.g., activator and / or diagnostic agent delivery devices) 100 of various shapes. The ophthalmic article 100 may include internal structures (e.g., holes) 110. In some figures, the ophthalmic article 100 may be an annular (e.g., extruded annular) shaped ophthalmic article 101 and / or a toroidal shaped ophthalmic article 106. Figure 1A illustrates a perspective view of an annular (e.g., extruded annular) shaped ophthalmic article 101. Figure 1B illustrates a perspective view of a toroidal shaped ophthalmic article 106. In some figures, the internal structure (e.g., holes) 110 may be a circular hole 120 in the annular (e.g., extruded annular) shaped ophthalmic article 101. In some figures, the internal structure (e.g., holes) 110 may be a circular hole 130 in the toroidal shaped ophthalmic article 106.

[0157]

[0247] Figures 2A, 2B, 2C, 2D, 2E, 2F, 2G, and 2H schematically illustrate other views (e.g., plan view, cross-sectional view) of examples of ophthalmic articles (e.g., activator and / or diagnostic agent delivery devices) 100 of various shapes. The ophthalmic article 100 may include an internal structure (e.g., a hole) 110 having an inner diameter or lateral edge 240. The ophthalmic article 100 may also include an outer diameter or outer edge 230, a cross-sectional thickness 250, and / or a wall thickness 260.

[0158]

[0248] Figure 2A illustrates a plan view of an annular (e.g., extruded annular) ophthalmic article 101. Figure 2B illustrates a cross-sectional view of the annular ophthalmic article 101. The annular ophthalmic article 101 includes an internal structure 110 which is a circular hole 120. The internal structure 110 includes an inner diameter or side edge 240. The inner diameter or side edge 240 may be an inner diameter 204. The annular ophthalmic article 101 may also include an outer diameter or outer edge 230, a cross-sectional thickness 250 and / or a wall thickness 260. The outer diameter or outer edge 230 may be an outer diameter 203. The cross-sectional thickness 250 may be a cross-sectional thickness 205. The wall thickness 260 may be a wall thickness 216.

[0159]

[0249] Figure 2C illustrates a plan view of a toroidal ophthalmic article 106. Figure 2D illustrates a cross-sectional view of a toroidal ophthalmic article 106. The toroidal ophthalmic article 106 includes an internal structure 110 which is a circular hole 130. The internal structure 110 includes an inner diameter or side edge 240. The inner diameter or side edge 240 may be an inner diameter 209. The toroidal ophthalmic article 106 may also include an outer diameter or outer edge 230, a cross-sectional thickness 250 and / or a wall thickness 260. The outer diameter or outer edge 230 may be an outer diameter 208. The cross-sectional thickness 250 may be a cross-sectional thickness 210. The wall thickness 260 may be a wall thickness 217.

[0160]

[0250] In some figures, the ophthalmic article 100 may be a square-shaped (e.g., extruded square) ophthalmic article 211. Figure 2E illustrates a plan view of the square-shaped (e.g., extruded square) ophthalmic article 211. Figure 2F illustrates a cross-sectional view of the square-shaped (e.g., extruded square) ophthalmic article 211. The square-shaped (e.g., extruded square) ophthalmic article 211 may include an internal structure (e.g., a hole) 110 which may be a square hole 255. The internal structure 110 includes an inner diameter or side edge 240. The inner diameter or side edge 240 may be a side edge 214. The square-shaped ophthalmic article 211 may also include an outer diameter or outer edge 230, a cross-sectional thickness 250 and / or wall thickness 260. The outer diameter or outer edge 230 may be a cross edge 213. The cross-sectional thickness 250 may be a cross-sectional thickness 215. A wall thickness of 260 could be 218.

[0161]

[0251] In some figures, the ophthalmic article 100 may be an octagonal ophthalmic article 270. Figure 2G illustrates a plan view of the octagonal ophthalmic article 270. Figure 2H illustrates a cross-sectional view of the octagonal ophthalmic article 270. The octagonal ophthalmic article 270 may include an internal structure (e.g., a hole) 110 which may be an octagonal hole 272. The internal structure 110 includes an inner diameter or side edge 240. The inner diameter or side edge 240 may be an inner diameter 274. The octagonal ophthalmic article 270 may also include an outer diameter or outer edge 230, a cross-sectional thickness 250 and / or a wall thickness 260. The outer diameter or outer edge 230 may be an outer edge 276. The cross-sectional thickness 250 may be a cross-sectional thickness 278. The wall thickness 260 may be a wall thickness 280.

[0162]

[0252] In some embodiments, the inner diameter 240 (e.g., inner diameter 204, inner diameter 209, inner diameter 274) or the inner surface length 240 (e.g., inner diameter 214) can be approximately 0.05 millimeters (mm) to 6 mm.

[0163]

[0253] In some embodiments, the inner diameter 240 or inner surface length 240 may be approximately 0.05 mm to 6 mm. In some embodiments, the inner diameter 240 or inner surface length 240 may be approximately 0.05 mm to 0.5 mm, approximately 0.05 mm to 0.1 mm, approximately 0.05 mm to 1.5 mm, approximately 0.05 mm to 2 mm, approximately 0.05 mm to 2.5 mm, approximately 0.05 mm to 3 mm, approximately 0.05 mm to 3.5 mm, approximately 0.05 mm to 4 mm, approximately 0.05 mm to 4.5 mm, approximately 0.05 mm to 5 mm, approximately 0.05 mm to 5.5 mm, approximately 0.05 mm to 6 mm, approximately 0.5 mm to 0.1 mm, approximately 0.5 mm to 1.5 mm, approximately 0.5 mm to 2 mm , about 0.5mm to about 2.5mm, about 0.5mm to about 3mm, about 0.5mm to about 3.5mm, about 0.5mm to about 4mm, about 0.5mm to about 4.5mm, about 0.5mm to about 5mm, about 0.5mm to about 5.5mm, about 0.5mm to about 6mm, about 0.1mm to about 1.5mm, Approximately 0.1mm to approximately 2mm, approximately 0.1mm to approximately 2.5mm, approximately 0.1mm to approximately 3mm, approximately 0.1mm to approximately 3.5mm, approximately 0.1mm to approximately 4mm, approximately 0.1mm to approximately 4.5mm, approximately 0.1mm to approximately 5mm, approximately 0.1mm to approximately 5.5mm, approximately 1mm to approximately 6mm, approximately 1.5m m~2mm, 1.5mm~2.5mm, 1.5mm~3mm, 1.5mm~3.5mm, 1.5mm~4mm, 1.5mm~4.5mm, 1.5mm~5mm, 1.5mm~5.5mm, 1.5mm~6mm, 2mm~2 .5mm, about 2mm to about 3mm, about 2mm to about 3.5mm, about 2mm to about 4mm, about 2mm to about 4.5mm, about 2mm to about 5mm, about 2mm to about 5.5mm, about 2mm to about 6mm, about 2.5mm to about 3mm, about 2.5mm to about 3.5mm, about 2.5mm to about 4mm, Approximately 2.5mm to approximately 4.5mm, approximately 2.5mm to approximately 5mm, approximately 2.5mm to approximately 5.5mm, approximately 2.5mm to approximately 6mm, approximately 3mm to approximately 3.5mm, approximately 3mm to approximately 4mm, approximately 3mm to approximately 4.5mm, approximately 3mm to approximately 5mm, approximately 3mm to approximately 5.5mm, approximately 3mm to approximately 6mm, approximately 3.5mm~4mm, 3.5mm~4.5mm, 3.5mm~5mm, 3.5mm~5.5mm, 3.5mm~6mm, 4mm~4.5mm, 4mm~5mm, 4mm~5.5mm, 4.5mm~5mm, 4.5mm~5.It could be 5mm, approximately 4.5mm to 6mm, approximately 5mm to 5.5mm, approximately 5mm to 6mm, or approximately 5.5mm to 6mm.

[0164]

[0254] In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device is at least about 0.05 mm, at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, at least about 1.2 mm, at least about 1.25 mm, at least about 1.3 mm, at least about 1.35 mm, at least about 1.4 mm, which may be at least about 1.45 mm, at least about 1.5 mm, at least about 1.55 mm, at least about 1.6 mm, at least about 1.65 mm, at least about 1.7 mm, at least about 1.75 mm, at least about 1.8 mm, at least about 1.85 mm, at least about 1.9 mm, at least about 1.95 mm, at least about 2 mm, at least about 2.05 mm, at least about 2.1 mm, at least about 2.15 mm, at least about 2.2 mm, at least about 2.25 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2.9 mm, at least about 3 mm, at least about 3.5 mm, at least about 4 mm, at least about 4.5 mm, at least about 5 mm, at least about 5.5 mm, or at least about 6 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be at least about 0.1 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be at least about 0.5 mm.

[0165]

[0255] In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device is at most about 0.05 mm, at most about 0.1 mm, at most about 0.15 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, and at most However, the maximum is approximately 0.65mm, the maximum is approximately 0.7mm, the maximum is approximately 0.75mm, the maximum is approximately 0.8mm, the maximum is approximately 0.85mm, the maximum is approximately 0.9mm, the maximum is approximately 0.95mm, the maximum is approximately 1mm, the maximum is approximately 1.05mm, the maximum is approximately 1.1mm, the maximum is approximately 1.15mm, the maximum is approximately 1.2mm, the maximum is approximately 1.25mm, the maximum is approximately 1.3mm, the maximum is approximately 1.35mm, and the maximum is approximately 1. 4mm, maximum approximately 1.45mm, maximum approximately 1.5mm, maximum approximately 1.55mm, maximum approximately 1.6mm, maximum approximately 1.65mm, maximum approximately 1.7mm, maximum approximately 1.75mm, maximum approximately 1.8mm, maximum approximately 1.85mm, maximum approximately 1.9mm, maximum approximately 1.95mm, maximum approximately 2mm, maximum approximately 2.05mm, maximum approximately 2.1mm, maximum approximately 2.15mm, maximum The maximum size can be approximately 2.2 mm, 2.25 mm, 2.3 mm, 2.4 mm, 2.5 mm, 2.6 mm, 2.7 mm, 2.8 mm, 2.9 mm, 3 mm, 3.5 mm, 4 mm, 4.5 mm, 5 mm, 5.5 mm, or 6 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be as small as 0.5 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be as small as 1 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be as small as 1.5 mm.

[0166]

[0256] In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device is approximately 0.05 mm, approximately 0.1 mm, approximately 0.15 mm, approximately 0.2 mm, approximately 0.25 mm, approximately 0.3 mm, approximately 0.35 mm, approximately 0.4 mm, approximately 0.45 mm, approximately 0.5 mm, approximately 0.55 mm, approximately 0.6 mm, approximately 0.65 mm, approximately 0.7 mm, approximately 0.75 mm, approximately 0.8 mm, approximately 0. 85mm, approximately 0.9mm, approximately 0.95mm, approximately 1mm, approximately 1.05mm, approximately 1.1mm, approximately 1.15mm, approximately 1.2mm, approximately 1.25mm, approximately 1.3mm, approximately 1.35mm, approximately 1.4mm, approximately 1.45mm, approximately 1.5mm, approximately 1.55mm, approximately 1.6mm, approximately 1.65mm, approximately 1.7mm, approximately 1.75mm, approximately 1.8mm, approximately 1.85mm, approximately 1.9mm , about 1.95mm, about 2mm, about 2.05mm, about 2.1mm, about 2.15mm, about 2.2mm, about 2.25mm, about 2.3mm, about 2.4mm, about 2.5mm, about 2.6mm , about 2.7mm, about 2.8mm, about 2.9mm, about 3mm, about 3.1mm, about 3.2mm, about 3.3mm, about 3.4mm, about 3.5mm, about 3.6mm, about 3.7mm, about 3.8 The dimensions may be approximately 3.9 mm, 4 mm, 4.1 mm, 4.2 mm, 4.3 mm, 4.4 mm, 4.5 mm, 4.6 mm, 4.7 mm, 4.8 mm, 4.9 mm, 5 mm, 5.1 mm, 5.2 mm, 5.3 mm, 5.4 mm, 5.5 mm, 5.6 mm, 5.7 mm, 5.8 mm, 5.9 mm, or 6 mm. In some embodiments, the inner diameter 240 or inner surface length 240 of the ophthalmic device may be approximately 0.5 mm.

[0167]

[0257] In some embodiments, the wall thickness 260 of the ophthalmic article (e.g., wall thickness 216, wall thickness 217, wall thickness 218, wall thickness 280) can be from about 0.001 mm to 3 mm. In some embodiments, the wall thickness of the ophthalmic article is from about 0.001 mm to about 0.01 mm, from about 0.001 mm to about 0.1 mm, from about 0.001 mm to about 0.2 mm, from about 0.001 mm to about 0.3 mm, from about 0.001 mm to about 0.4 mm, from about 0.001 mm to about 0.5 mm, from about 0.001 mm to about 1 mm, from about 0.001 mm to about 1.5 mm, from about 0.001 mm to about 2 mm, from about 0.001 mm to about 2.5 mm, from about 0.001 mm to about 3 mm, from about 0.01 mm to about 0.1 mm, from about 0.01 mm to about 0.2 mm, from about 0.01 mm to about 0.3 mm, from about 0.01 mm to about 0.4 mm, from about 0.01 mm to about 0.5 mm, from about 0.01 mm to about 1 mm, from about 0.01 mm to about 1.5 mm, from about 0.01 mm to about 2 mm, from about 0.01 mm to about 2.5 mm, from about 0.01 mm to about 3 mm, from about 0.1 mm to about 0.2 mm, from about 0.1 mm to about 0.3 mm, from about 0.1 mm to about 0.4 mm, from about 0.1 mm to about 0.5 mm, from about 0.1 mm to about 1 mm, from about 0.1 mm to about 1.5 mm, from about 0.1 mm to about 2 mm, from about 0.1 mm to about 2.5 mm, from about 0.1 mm to about 3 mm, from about 0.2 mm to about 0.3 mm, from about 0.2 mm to about 0.4 mm, from about 0.2 mm to about 0.5 mm, from about 0.2 mm to about 1 mm, from about 0.2 mm to about 1.5 mm, from about 0.2 mm to about 2 mm, from about 0.2 mm to about 2.5 mm, from about 0.2 mm to about 3 mm, from about 0.3 mm to about 0.4 mm, from about 0.3 mm to about 0.5 mm, from about 0.3 mm to about 1 mm, from about 0.3 mm to about 1.5 mm, from about 0.3 mm to about 2 mm, from about 0.3 mm to about 2.5 mm, from about 0.3 mm to about 3 mm, from about 0.4 mm to about 0.5 mm, from about 0.4 mm to about 1 mm, from about 0.4 mm to about 1.5 mm, from about 0.4 mm to about 2 mm, from about 0.4 mm to about 2.5 mm, from about 0.4 mm to about 3 mm, from about 0.5 mm to about 1 mm, from about 0.5 mm to about 1.5 mm, from about 0.5 mm to about 2 mm, from about 0.5 mm to about 2.5 mm, from about 0.5 mm to about 3 mm, from about 1 mm to about 1.5 mm, from about 1 mm to about 2 mm, from about 1 mm to about 2.5 mm, from about 1 mm to about 3 mm, from about 1.5 mm to about 2 mm, from about 1.5 mm to about 2.5 mm, from about 1.5 mm to about 3 mm, from about 2 mm to about 2.5 mm, from about 2 mm to about 3 mm, or from about 2.5 mm to about 3 mm.In some embodiments, the wall thickness of the ophthalmic article may be approximately 0.1 mm to approximately 1 mm. In some embodiments, the wall thickness of the ophthalmic article may be approximately 0.1 mm to approximately 1.5 mm.

[0168]

[0258] In some embodiments, the wall thickness of the ophthalmic article is at least about 0.001 mm, at least about 0.005 mm, at least about 0.01 mm, at least about 0.02 mm, at least about 0.03 mm, at least about 0.04 mm, at least about 0.05 mm, at least about 0.06 mm, at least about 0.07 mm, at least about 0.08 mm, at least about 0.09 mm, at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm The wall thickness may be at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.2 mm, at least about 1.4 mm, at least about 1.6 mm, at least about 1.8 mm, at least about 2 mm, at least about 2.2 mm, at least about 2.4 mm, at least about 2.6 mm, at least about 2.8 mm, or at least about 3 mm. In some embodiments, the wall thickness of the ophthalmic article may be at least about 0.1 mm. In some embodiments, the wall thickness of the ophthalmic article may be at least about 0.5 mm. In some embodiments, the wall thickness of the ophthalmic article may be at least about 1 mm.

[0169]

[0259] In some embodiments, the wall thickness of the ophthalmic article is at most about 0.001 mm, at most about 0.005 mm, at most about 0.01 mm, at most about 0.02 mm, at most about 0.03 mm, at most about 0.04 mm, at most about 0.05 mm, at most about 0.06 mm, at most about 0.07 mm, at most about 0.08 mm, at most about 0.09 mm, at most about 0.1 mm, at most about 0.15 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.4 It may be 5mm, at most about 0.5mm, at most about 0.55mm, at most about 0.6mm, at most about 0.65mm, at most about 0.7mm, at most about 0.75mm, at most about 0.8mm, at most about 0.85mm, at most about 0.9mm, at most about 0.95mm, at most about 1mm, at most about 1.2mm, at most about 1.4mm, at most about 1.6mm, at most about 1.8mm, at most about 2mm, at most about 2.2mm, at most about 2.4mm, at most about 2.6mm, at most about 2.8mm, or at most about 3mm. In some embodiments, the wall thickness of the ophthalmic article may be at most about 0.5mm. In some embodiments, the wall thickness of the ophthalmic article may be at most about 1mm. In some embodiments, the wall thickness of the ophthalmic article may be at most about 1.5mm.

[0170]

[0260] In some embodiments, the wall thickness of the ophthalmic article may be about 0.001 mm, about 0.005 mm, about 0.01 mm, about 0.02 mm, about 0.03 mm, about 0.04 mm, about 0.05 mm, about 0.06 mm, about 0.07 mm, about 0.08 mm, about 0.09 mm, about 0.1 mm, about 0.11 mm, about 0.12 mm, about 0.13 mm, about 0.14 mm, about 0.15 mm, about 0.16 mm, about 0.17 mm, about 0.18 mm, about 0.19 mm, about 0.2 mm, about 0.21 mm, about 0.22 mm, about 0.23 mm, about 0.24 mm, about 0.25 mm, about 0.26 mm, about  0.27 mm, about 0.28 mm, about 0.29 mm, about 0.3 mm, about 0.31 mm, about 0.32 mm, about 0.33 mm, about 0.34 mm, about 0.35 mm, about 0.36 mm, about   0.37 mm, about 0.38 mm, about 0.39 mm, about 0.4 mm, about 0.41 mm, about 0.42 mm, about 0.43 mm, about 0.44 mm, about 0.45 mm, about 0.46 mm, about 0.47 mm, about 0.48 mm, about 0.49 mm, about 0.5 mm, about 0.51 mm, about 0.52 mm, about 0.53 mm, about 0.54 mm, about 0.55 mm, about 0.56 mm, about 0.57 mm, about 0.58 mm, about 0.59 mm, about 0.6 mm, about 0.61 mm, about 0.62 mm, about 0.63 mm, about 0.64 mm, about 0.65 mm, about 0.66 mm, about 0.67 mm, about 0.68 mm, about 0.69 mm, about 0.7 mm, about 0.71 mm, about 0.72 mm, about 0.73 mm, about 0.74 mm, about 0.75 mm, about 0.76 mm, about 0.77 mm, about 0.78 mm, about 0.79 mm, about 0.8 mm, about 0.81 mm, about 0.82 mm, about 0.83 mm, about 0.84 mm, about 0.85 mm, about 0.86 mm, about 0.87 mm, about 0.88 mm, about 0.89 mm, about 0.9 mm, about 0.91 mm, about 0.92 mm, about 0.93 mm, about 0.94 mm, about 0.95 mm, about 0.96 mm, about 0.97 mm, about 0.98 mm, about 0.99 mm, about 1 mm, about 1.1 mm, about 1.2 mm, about 1.3 mm, about 1.4 mm, about   1.5 mm, about 1.6 mm, about 1.7 mm, about 1.8 mm, about 1.9 mm, about 2 mm, about 2.1 mm, about 2.2 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, or about 3 mm.In some embodiments, the wall thickness of the ophthalmic article may be approximately 0.7 mm.

[0171]

[0261] In some embodiments, when the ophthalmic article is bonded to (e.g., attached to) a portion of an ophthalmic device (e.g., the haptics of an IOL), it extends beyond the portion of the ophthalmic device (e.g., the haptics of an IOL) by approximately 0.32 mm or less. In some embodiments, when an ophthalmic article is bonded to (e.g., attached to) a portion (e.g., haptics) of an ophthalmic device (e.g., IOL), it extends beyond the portion of the ophthalmic device (e.g., haptics of the IOL) to a maximum of approximately 3 mm, 2.9 mm, 2.8 mm, 2.7 mm, 2.6 mm, 2.5 mm, 2.4 mm, 2.3 mm, 2.2 mm, 2.1 mm, 2 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, or 0.1 mm.

[0172]

[0262] In some embodiments, when an ophthalmic article is bonded (e.g., adhered) to a portion (e.g., haptics) of an ophthalmic device (e.g., IOL), it extends beyond the portion (e.g., haptics) of the ophthalmic device (e.g., IOL) by at least about 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2 mm, 2.1 mm, 2.2 mm, 2.3 mm, 2.4 mm, 2.5 mm, 2.6 mm, 2.7 mm, 2.8 mm, 2.9 mm, or 3 mm or more.

[0173]

[0263] In some embodiments, when an ophthalmic article is bonded (e.g., adhered) to a portion (e.g., haptics) of an ophthalmic device (e.g., IOL), it extends beyond the portion (e.g., haptics) of the ophthalmic device (e.g., IOL) by approximately 0.1 mm, approximately 0.2 mm, approximately 0.3 mm, approximately 0.4 mm, approximately 0.5 mm, approximately 0.6 mm, approximately 0.7 mm, approximately 0.8 mm, approximately 0.9 mm, approximately 1 mm, approximately 1.1 mm, approximately 1.2 mm, approximately 1.3 mm, approximately 1.4 mm, approximately 1.5 mm, approximately 1.6 mm, approximately 1.7 mm, approximately 1.8 mm, approximately 1.9 mm, approximately 2 mm, approximately 2.1 mm, approximately 2.2 mm, approximately 2.3 mm, approximately 2.4 mm, approximately 2.5 mm, approximately 2.6 mm, approximately 2.7 mm, approximately 2.8 mm, approximately 2.9 mm, or approximately 3 mm.

[0174]

[0264] In some embodiments, the cross-sectional thickness 250 of the ophthalmic article (for example, cross-sectional thickness 205, cross-sectional thickness 210, cross-sectional thickness 215, cross-sectional thickness 278) may be approximately 0.05 mm to 3 mm.

[0175]

[0265] In some embodiments, the cross-sectional thickness of the ophthalmic article may be approximately 0.01 mm to approximately 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be approximately 0.01 mm to approximately 0.05 mm, approximately 0.01 mm to approximately 0.1 mm, approximately 0.01 mm to approximately 0.5 mm, approximately 0.01 mm to approximately 1 mm, approximately 0.01 mm to approximately 1.5 mm, approximately 0.01 mm to approximately 2 mm, approximately 0.01 mm to approximately 2.5 mm, approximately 0.01 mm to approximately 3 mm, approximately 0.01 mm to approximately 3.5 mm, approximately 0.01 mm to approximately 4 mm, approximately 0.05 mm to approximately 0.1 mm, approximately 0.05 mm~about 0.5mm, about 0.05mm~about 1mm, about 0.05mm~about 1.5mm, about 0.05mm~about 2mm, about 0.05mm~about 2.5mm, about 0.05mm~about 3mm, about 0.05mm~about 3.5mm , about 0.05mm to about 4mm, about 0.1mm to about 0.5mm, about 0.1mm to about 1mm, about 0.1mm to about 1.5mm, about 0.1mm to about 2mm, about 0.1mm to about 2.5mm, about 0.1mm to about 3mm, about 0.1mm to about 3.5mm, about 0.1mm to about 4mm, about 0.5mm to about 1mm, about 0.5mm to about 1.5mm, about 0.5mm to about 2mm, about 0.5mm to about 2.5mm, about 0.5mm to about 3mm, about 0. 5mm to about 3.5mm, about 0.5mm to about 4mm, about 1mm to about 1.5mm, about 1mm to about 2mm, about 1mm to about 2.5mm, about 1mm to about 3mm, about 1mm to about 3.5mm, about 1mm to about 4mm, about 1.5 The cross-sectional thickness may be approximately 0.1 mm to 2 mm, approximately 1.5 mm to 2.5 mm, approximately 1.5 mm to 3 mm, approximately 1.5 mm to 3.5 mm, approximately 1.5 mm to 4 mm, approximately 2 mm to 2.5 mm, approximately 2 mm to 3 mm, approximately 2 mm to 3.5 mm, approximately 2 mm to 4 mm, approximately 2.5 mm to 3 mm, approximately 2.5 mm to 3.5 mm, approximately 2.5 mm to 4 mm, approximately 3 mm to 3.5 mm, approximately 3 mm to 4 mm, or approximately 3.5 mm to 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be approximately 0.1 mm to 1 mm.

[0176]

[0266] In some embodiments, the cross-sectional thickness of the ophthalmic article may be at least about 0.01 mm, at least about 0.05 mm, at least about 0.1 mm, at least about 0.5 mm, at least about 1 mm, at least about 1.5 mm, at least about 2 mm, at least about 2.5 mm, at least about 3 mm, at least about 3.5 mm, or at least about 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at least about 0.1 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at least about 0.5 mm.

[0177]

[0267] In some embodiments, the cross-sectional thickness of the ophthalmic article may be at most about 0.01 mm, at most about 0.05 mm, at most about 0.1 mm, at most about 0.5 mm, at most about 1 mm, at most about 1.5 mm, at most about 2 mm, at most about 2.5 mm, at most about 3 mm, at most about 3.5 mm, or at most about 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at most about 1 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at most about 1.5 mm.

[0178]

[0268] In some embodiments, the outer diameter 230 (e.g., outer diameter 203, outer diameter 208, outer diameter 276) or outer edge 230 (e.g., outer diameter 213) may be about 0.1 mm to 6 mm. In some embodiments, the outer diameter or outer edge of the ophthalmic article may be about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 2.5 mm, about 0.1 mm to about 3 mm, about 0.1 mm to about 3.5 mm, about 0.1 mm to about 4 mm, about 0.1 mm to about 4.5 mm, about 0.1 mm to about 5 mm, about 0.1 mm to about 5.5 mm, about 1 mm to about 6 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5mm, about 1.5mm to about 3mm, about 1.5mm to about 3.5mm, about 1.5mm to about 4mm, about 1.5mm to about 4.5mm, about 1.5mm to about 5mm, about 1.5mm to about 5.5mm, about 1 .5mm to about 6mm, about 2mm to about 2.5mm, about 2mm to about 3mm, about 2mm to about 3.5mm, about 2mm to about 4mm, about 2mm to about 4.5mm, about 2mm to about 5mm, about 2mm to about 5.5mm , about 2mm to about 6mm, about 2.5mm to about 3mm, about 2.5mm to about 3.5mm, about 2.5mm to about 4mm, about 2.5mm to about 4.5mm, about 2.5mm to about 5mm, about 2.5mm to about 5.5 mm, about 2.5mm to about 6mm, about 3mm to about 3.5mm, about 3mm to about 4mm, about 3mm to about 4.5mm, about 3mm to about 5mm, about 3mm to about 5.5mm, about 3mm to about 6mm, about 3.5mm The outer diameter or edge of the ophthalmic article may be approximately 4mm, approximately 3.5mm to approximately 4.5mm, approximately 3.5mm to approximately 5mm, approximately 3.5mm to approximately 5.5mm, approximately 3.5mm to approximately 6mm, approximately 4mm to approximately 4.5mm, approximately 4mm to approximately 5mm, approximately 4mm to approximately 5.5mm, approximately 4.5mm to approximately 5mm, approximately 4.5mm to approximately 5.5mm, approximately 4.5mm to approximately 6mm, approximately 5mm to approximately 5.5mm, approximately 5mm to approximately 6mm, or approximately 5.5mm to approximately 6mm. In some embodiments, the outer diameter or edge of the ophthalmic article may be approximately 0.1mm to approximately 1.5mm. In some embodiments, the outer diameter or edge of the ophthalmic article may be approximately 0.5mm to approximately 1.5mm. In some embodiments, the outer diameter or edge of the ophthalmic article may be approximately 0.5mm to approximately 2mm.

[0179]

[0269] In some embodiments, the outer diameter or outer edge of the ophthalmic article is at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, at least about 1.2 mm, at least about 1.25 mm, at least about 1.3 mm, at least about 1.35 mm, at least about 1.4 mm, at least about 1.45 The outer diameter or outer edge of the ophthalmic article may be at least about 1.5 mm, at least about 1.55 mm, at least about 1.6 mm, at least about 1.65 mm, at least about 1.7 mm, at least about 1.75 mm, at least about 1.8 mm, at least about 1.85 mm, at least about 1.9 mm, at least about 1.95 mm, at least about 2 mm, at least about 2.05 mm, at least about 2.1 mm, at least about 2.15 mm, at least about 2.2 mm, at least about 2.25 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2.9 mm, at least about 3 mm, at least about 3.5 mm, at least about 4 mm, at least about 4.5 mm, at least about 5 mm, at least about 5.5 mm, or at least about 6 mm. In some embodiments, the outer diameter or outer edge of the ophthalmic article may be at least about 0.5 mm. In some embodiments, the outer diameter or outer edge of the ophthalmic article may be at least about 1 mm. In some embod...

Claims

1. a. A biocompatible matrix containing poly(lactide-co-caprolactone); and b. Active agents that are corticosteroids, nonsteroidal anti-inflammatory drugs, or antibiotics. An ophthalmic article comprising an internal structure configured to contact the outer surface of the haptics of an intraocular lens (IOL) and to be adjacent to and encompass the periphery of the outer surface of the haptics of the intraocular lens (IOL), wherein the periphery or maximum width of the internal structure is less than or equal to the periphery or maximum width of the haptics of the IOL.

2. The ophthalmic article according to claim 1, wherein the poly(lactide-co-caprolactone) comprises about 20% to about 60% by weight of caprolactone monomer and about 40% to 80% by weight of lactide monomer.

3. The ophthalmic article according to claim 1 or 2, wherein the poly(lactide-co-caprolactone) comprises about 40% by weight of caprolactone monomer and about 60% by weight of lactide monomer.

4. The aforementioned article: (i) Having a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry, and / or (ii) Having an elastic modulus of at most about 10 MPa as measured by dynamic mechanical analysis, An ophthalmic article according to any one of claims 1 to 3.

5. The article has at least about 100% elongation at the breaking point when measured at about 18°C ​​to 24°C. An ophthalmic article according to any one of claims 1 to 4, which may have a breaking point elongation of approximately 500% to 1500% at approximately 18°C ​​to 24°C.

6. A kit for ophthalmic delivery, a. (1) a biocompatible matrix containing poly(lactide-co-caprolactone); and (2) one or more ophthalmic articles containing an active agent which is a corticosteroid, a nonsteroidal anti-inflammatory drug, or an antibiotic; and b. One or more intraocular lenses containing one or more haptics The kit includes, wherein the one or more ophthalmic articles include an internal structure configured to contact the outer surface of the one or more haptics of the one or more intraocular lenses and to be enclosed adjacent to the periphery of the outer surface of the one or more haptics of the one or more intraocular lenses, wherein the periphery or maximum width of the internal structure is less than or equal to the periphery or maximum width of the haptics of the IOL.

7. The kit according to claim 6, wherein about one of the one or more ophthalmic articles is coupled to about one of the one or more haptics of the one or more intraocular lenses.

8. The poly(lactide-co-caprolactone) comprises approximately 20% to 60% by weight of the caprolactone monomer and approximately 40% to 80% by weight of the lactide monomer. A kit according to claim 6 or 7, comprising:

9. The kit according to any one of claims 6 to 8, wherein the one or more ophthalmic articles includes an internal structure for bonding around the one or more haptics of the one or more intraocular lenses.

10. An ophthalmic article according to any one of claims 1 to 5 for use in a method of treating or preventing a disease, the method comprising the step of implanting an intraocular lens (IOL) for sustained intraocular drug delivery into an eye of a subject requiring the IOL, the IOL comprising one or more drug-releasing articles bound thereto, the one or more drug-releasing articles comprising one or more activators which are corticosteroids, nonsteroidal anti-inflammatory drugs, or antibiotics, the one or more drug-releasing articles releasing the one or more activators within seven days after implantation, resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit-lamp biomicroscopy, or ophthalmic pain being eliminated as measured by a 10-point visual analog scale.

11. The ophthalmic article according to any one of claims 1 to 5 and 10, wherein the biocompatible matrix is ​​sufficiently compressible to accommodate injection by an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm, and / or the ophthalmic article has a tensile strength of at least about 0.5 megapascals (MPa).

12. The ophthalmic article according to claim 10 or 12, wherein one or more drug-releasing articles have a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry.

13. The biocompatible matrix has an injector tip inner diameter of approximately 0.5 mm to 3 mm. An ophthalmic article according to any one of claims 1 to 5 and 10 to 12, which is sufficiently compressible to accommodate injection by an IOL injector.

14. The ophthalmic article according to any one of claims 1 to 5 and 10 to 13, wherein the biocompatible matrix is ​​sufficiently elastic to return to its original shape after injection by an IOL injector having an injector tip inner diameter of about 0.5 mm to 3 mm.

15. The ophthalmic article according to any one of claims 1 to 5 and 10 to 14, wherein the copolymer is a random copolymer, a block copolymer, or a gradient copolymer.

16. An ophthalmic article according to any one of claims 1 to 5 and 10 to 15, wherein when the ophthalmic article is attached around the haptics of the IOL, it extends beyond the haptics of the IOL by about 0.32 mm or less.

17. An ophthalmic article according to any one of claims 1 to 5 and 10 to 16, comprising an outer diameter of up to approximately 1.5 mm.

18. An ophthalmic article according to any one of claims 1 to 5 and 10 to 17, which is sufficiently physically stable in a physiological environment so as not to significantly change shape within at least 7 days after implantation of the ophthalmic article in the target eye.

19. An ophthalmic article according to any one of claims 1 to 5 and 10 to 18, comprising approximately 1 μg to 800 μg of an activator.

20. An ophthalmic article according to any one of claims 10 to 19, wherein one or more drug-releasing articles are in contact with the outer surface of one or more haptics of an intraocular lens and are contained adjacent to the periphery of the outer surface of one or more haptics of an intraocular lens, and at least two drug-releasing articles are in contact with the outer surface of one or more haptics of an intraocular lens and are contained adjacent to the periphery of the outer surface of one or more haptics of an intraocular lens.

21. The kit according to any one of claims 6 to 9, wherein at least two ophthalmic articles are in contact with the outer surface of one or more haptics of an intraocular lens and are enclosed adjacent to the outer surface of one or more haptics of an intraocular lens.

Images